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The innate immune system relies on several pattern recognition receptors (PRRs) to identify
pathogen associated molecular patterns (PAMPs). One of the most prominent non-clonal, germline
encoded but yet not fully characterized PRR group are the NOD-like receptors (NLRs). Here I aim
to characterize a hitherto rarely described member of the NLRs named NOD-like receptor CARD
domain containing 3 (NLRC3). Recent studies indicated, that NLRC3 is a cytosolic receptor which
negatively regulates T cell function.
This thesis utilizes several experimental approaches to access the cellular localization of NLRC3,
its functional interactions, and role in inflamed tissue. Microscopical studies showed, that NLRC3
is localized in the cytoplasm. Analysis of different organs indicated, that NLRC3 transcript level
are elevated in immune relevant tissues, but not in the intestinal tract. A Y2H screen indicated a po-
tential interaction with the mitochondrial protein IMMT/Mitofilin. Although a direct interaction
remained elusive, NLRC was detected in close spatial proximity of mitochondria via immune-
fluorescence and identified in mitochondrial lysates. NLRC3 was found to interfere with NFκB
signaling in a dose dependent manner. Dual luciferase assays were performed revealing connec-
tions to TRAF6 and ERSE. NLRC3 seems to negatively regulate the TRAF6 mediated NFκB
response. In combination with a potent stressor, such as tunicamycin elevates NLRC3 the ERSE
promoter activity. This reaction connects NLRC3 to cellular mechanisms of the unfolded protein
response, and subsequently to mitochondrial stress reactions. NLRC3 was found to be downregu-
lated in biopsies of WG patients. During this thesis Nlrc3+/+ and Nlrc3-/- mice were bred and uti-
lized in several experiments. Cytokine level in bone marrow derived macrophages varied between
Nlrc3+/+ and Nlrc3-/- in response to LPS stimulation. A DSS induced colitis was conducted and
revealed, that NLRC3 seems to be beneficial for survival and disease severity. These experiments
significantly enlarged the knowledge about NLRC3, pointing at the protective role of NLRC3





Das angeborene Immunsystem basiert auf einer Vielzahl von Mustererkennenden Rezep-
toren (PRR, von engl. pattern recognition receptors) zur Identifikation molekularer pathogen-
assoziierter Muster. Eine der bekanntesten nicht-klonalen, keimbahn-kodierten, jedoch noch un-
vollständig beschriebene PRR-Gruppe sind die NOD ähnlichen Rezeptoren (NLR, von engl. NOD-
like receptors). Diese Arbeit hat die Charakterisierung eines bisher kaum beschrieben Mitglieds
der NLRs, dem Protein NLRC3 zum Ziel. Bisherige Studien zeigen, dass NLRC3 ein zytosolischer
Rezeptor ist, der einen negativ-regulatorischen Einfluss auf T-Zellen aufweist.
Im Verlauf dieser Arbeit wurden unterschiedliche experimentelle Ansätze verwendet, um die zel-
luläre Lokalisation von NLRC3, seine funktionellen Interaktionen, sowie die Rolle in entzündetem
Gewebe zu charakterisieren. Mikroskopische Studien konnten zeigen, dass NLRC3 im Zytoplasma
verortet ist. Die Untersuchung verschiedener Gewebe ergab dabei, dass sich NLRC3 hauptsächlich
in immunrelevanten Geweben, nicht jedoch im Gastrointestinaltrakt nachweisen lies. Nachdem ein
Hefe-2-Hybrid Experiment das mitochondriale Protein IMMT/Mitofilin als potentiellen Interak-
tionspartner für NLRC3 gezeigt hatte, konnte NLRC3 durch Immunfluoreszenzanalysen in unmit-
telbarer Nähe von Mitochondrien detektiert werden. Zudem gelang die Identifikation von NLRC3
in Mitochondrienlysaten. Der Einfluss von NLRC3 auf den NFκB Signalweg ist dosisabhängig
und konnte mittels Luziferase-Test auch im Zusammenhang mit TRAF6 und ERSE gezeigt wer-
den. NLRC3 scheint die TRAF6 vermittelte NFκB Antwort negativ zu regulieren. In Kombination
mit Tunicamycin führte NLRC3 zu einer erhöhten ERSE Promotoraktivität. Diese Ergebnisse brin-
gen NLRC3 in Zusammenhang mit den zellulären Mechanismen der Antwort auf Proteinfehlfal-
tung und damit schließlich zu mitochondrialen Stressreaktionen. Zudem konnte gezeigt werden,
dass NLRC3 in WG Patienten herab reguliert ist. Für diese Arbeit wurden zusätzlich Nlrc3+/+
und Nlrc3-/- Mäuse gezüchtet und in verschiedenen Experimenten untersucht. Die Zytokinspiegel
in Makrophagen des murinen Knochenmarks unterschieden sich zwischen den beiden Genotypen
nach Stimulation mit LPS. In einer DSS induzierten Kolitis konnte gezeigt werden, dass sich
NLRC3 in Bezug auf Überlebensrate und Schwere der Krankheit positiv auswirkte.
Die vorliegenden Experimente erweitern deutlich das bisherige Wissen über NLRC3. Die pro-
tektive Wirkung von NLRC3 während Zellstress und Entzündung stellt einen bisher unbekannten




The human body is composed of approximately 1013 cells. At the same time the body is colonized
by 1014 bacteria, representing up to 3 % of the total body mass [1, 2]. A mutualistic co-existence of
host and microbes is based on the homeostatic relations between the two. To maintain the home-
ostasis the host needs effective monitoring systems to recognize imbalanced microbial composi-
tions or bacteria/constituents like endotoxins or flagellin in "off limit" areas like the bloodstream
or internal organs. A mutual gut bacterium beneficial to the hosts’ gut may cause severe infections
upon breaching the intestinal mucosa and reaching the bloodstream.
Within the human body, several barrier types occur. Barriers rely on chemical properties like pH
values, on physical resistance as displayed by dermis or mucus, or on biological activities like anti
microbial peptides [3, 4, 5, 6].
The mucus layer may be breached actively by pathogenic bacteria or passively due to a weakened
mucus layer as observed in ulcerative colitis, where the stratified mucus layer becomes penetrable
[7]. Thus the constant monitoring of the microbial load, search for invading pathogens and, if
necessary a fast and appropriate response are achieved by the immune system.
2.1 The immune system
The immune system can be subdivided into two interacting parts - the innate and adaptive. The
innate immune system is germ-line encoded, highly conserved, and the first to be activated. It
relies mostly on a variety of conserved receptors and a set of responding cells, such as leukocytes,
dendritic cells, and macrophages. The innate immune response, once triggered, is non-specific and
does not provide memory for long lasting immunity.
The adaptive immune system develops during life, is strongly influenced by its environment, and
relies on humoral and cellular components. The humoral response is based on specific antibodies
and B lymphocytes honed against matching antigens. The cellular response is based on T lympho-
cytes. Both, the B and the T cells are key to immunological memory [8]. Additionally, the innate
immune system elicits an immediate response in mere hours, in contrast to the adaptive immune
response which may take days to weeks to fully form.
The immune system has three main functions: first the recognition of a diverse array of pathogens,
such as pathogenic bacteria, viruses, fungi, and protists. Second, killing of those pathogens, and
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third all the while tolerating the host [9]. Thus the immune system is also multi-layered surveil-
lance and response mechanism to discriminate between pathogenic and mutualistic important bac-
teria [10].
The experiments and results presented in this thesis focus on the innate immune system.
2.1.1 Inflammation
Inflammation is a non-specific immune response of an organism toward injury [11]. Inflammatory
processes may be divided in acute, described by an immediate onset and limited duration, and
chronic with delayed onset and a potential life long duration. Clinical cardinal sinuses are since
ancient times rubor et calor cum tumor et dolor (et functio laesa) [12]. Activating the innate
immune system results generally in inflammation, recruitment of phagocytes and the reduction and
release of a diverse repertoire of defensive molecules and substances like anti-microbial peptides
and reactive oxygen species (ROS) [13, 14]. A malfunction of T lymphocytes or a dysregulation
of cytokines and chemokines may lead to an uncontrolled inflammation reaction affecting both the
adaptive and innate immune system [15]. Hence, research on molecular inflammatory processes is
of importance for the understanding of innate immunity.
2.1.2 Pattern recognition receptors
The innate immune system enables eukaryotes to detect potential pathogenic elicitors along
anatomical sites exposed to microbes and other pathogens. It relies on germline-encoded pattern
recognition receptors (PRRs) to identify conserved molecular motifs among microbial species,
known as pathogen-associated molecular patterns (PAMPs), and danger/damage-associated
molecular patterns (DAMPs) [16]. PAMPs are a diverse and dynamic group of molecules, ranging
from molecular CpGs to endotoxins, such as lipopolysaccharides (LPS) [17, 18]. DAMPs encom-
pass endogenous molecules released from damaged cells as well as signals, such as pathogen-
derived proteins, lipids, alterations of ion levels, crystalline materials, and cytosolic mitochondrial
DNA (mtDNA) [19]. The most prominent non-clonal, germline-encoded PRRs are subdivided
into five groups executing different functions. Toll-like receptors (TLR), retinoic acid inducible
gene (RIG)-like receptors (RLR), absent in melanoma (AIM)-2-like receptors (ALRs), C-type
lectins (CTLs), and Nucleotide-binding oligomerization domain and leucine-rich repeat contain-
ing (NOD)-like receptors (NLR) [19]. TLRs detect extracellular PAMPs, such as flagellin, LPS
or intracellular viral RNA [20, 21, 22, 23]. RLRs are found to act as a receptor for dsRNA [24],
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while ALRs detect cytosolic dsDNA [25]. CTLs are capable of binding terminal monosaccharide
residues characteristic of bacterial and fungal cell surfaces [26]. NLRs are a diverse group and
still not fully characterized. NLRs represent a group of receptors and mediators which are located
within the cytosol, thereby acting as intracellular receptors for invading PAMPs and possibly for
cytosolic DAMPs. In general, the activation of PRRs trigger the recruitment of adapter molecules




NOD-like receptor proteins belong to the protein family of signal transduction ATPases with
numerous domains (STAND) subclade of the AAA+ ATPase superfamily [28]. They are charac-
terized by a modular organization of three to four different structural elements. At the N-terminus
highly-variable domains represent the most unique feature to distinguish the different protein
family members. The N-terminus features acidic transactivation domains (AD), baculovirus in-
hibitor of apoptosis protein repeat (BIR)-like domains, caspase recruitment domains (CARD) or
pyrin domains PYD domains [29, 30]. Most NLRs share the centrally located nucleotide-binding
domain (NBD) or NACHT (NLR family apoptosis inhibitory protein, Class II transcription ac-
tivator, Heterokaryon incompatibility-E, and Telomerase-associated protein-1). The C-terminus
has a variable number of leucine-rich repeats (LRR). Some of this classifications are still matter
of debate as for NLRC3, NLRC5, and NLRX1. The domain structures are given in Fig. 2.1.
General induction and response
NLRs play a crucial role in sensing invading pathogen components and in initiating a molecular
defense cascade. A well observed, albeit not generally described mechanism of NLR induction is
based upon ligand binding followed by conformational changes and oligomerization. The NLR-
mediated response includes the attraction of leukocytes, activation of defensins, initiating a pro-
inflammatory response, resulting in caspase-1 processing, forming inflammasomes, modulating
immune functions, and playing crucial, albeit not fully understood roles in development [19, 31,
32, 33, 34, 35, 36].
5
INTRODUCTION
Fig. 2.1: Domain architecture of NLR proteins. The architecture of the human NLR family with regard to their
domain organization and resulting subfamily structure. Abbreviations used: AD: acidic activation domain; BIR: bac-
ulovirus inhibitor of apoptosis protein repeat; CARD: caspase recruitment domain; CIITA: class II transcription acti-
vator; FIIND: function to find; LRR: leucine rich repeats; NACHT/NBD: nucleotide binding domain named for NAIP,
CIITA, HET-E, and TP-1 protein families with this domain; NOD: Nucleotide-binding, oligomerization domain and
leucine-rich repeat containing protein; NOD3: NLRC3; NLR: NOD-like receptor; PYD: pyrin domain.
General occurrence
NLR have been found in a variety of organisms from different kingdoms including fungi, plants,
and animals. Higher plants contain up to 508 different NLRs while the human genome codes for
about 23 different NLRs [37, 38, 39]. Molecular evidence suggests that NLRs evolved to a high
pathogen specifity [40]. The tripartite structure of NLRs has been found in mammals to a high
diversity and was discovered in plants, too. In animals, NLRs show a strong similarity to plant re-
sistance proteins which recognize virulence factors [35, 41]. Since plants lack an adaptive immune
system or any yet known specialized immune cells, they solely rely on the innate immune system
to detect non-self components and combat against invading pathogens [42]. The recognition of
invading pathogens in plants and the detection by R proteins is closely related to rapid cell death
[43, 44].
General nomenclature
NLRs have been classified by two different systems. Schroder et al. distinguished the NLRs in
three phylogenetic subclades (NOD, IPAF, and NLRP) [33], while others focused on a classifica-
tion by additional domains [30, 45]. Due to a rising amount of members and therefore different
6
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names, the NLR nomenclature has been standardized in 2008. The agreed nomenclature will be
used as further reference [30].
2.1.4 Evolution of NLRs
Phylogenetic analysis indicates that NLRC3 is basal to all NACHT-domain containing proteins
found in tetrapods [46]. Comparative analysis to the genomic sequences of chicken (Gallus gal-
lus) led to the hypothesis that NOD3/NLRC3 is basal to the other groups of NACHT containing
proteins and originated together with NOD1 and CIITA as a result of a gene duplication event be-
fore the bird-mammal divergence, which occurred approximately 310 million years ago [46, 47].
Fig. 2.2: Phylogenetic analysis of NACHT-domain containing proteins among tetrapods. Results derived from
Hughes et al. [46]. Numbers on the branches are confidence level of standard error test; only values ≥ 95% are shown.
Abbreviations used: CAF/CAG: prefix of accession number; CIITA: class II transcription activator; NOD: nucleotide-
binding oligomerization domain; NOD3: NLRC3.
Additionally, a more recent phylogenetic analysis on mammalian, zebrafish , and the catfish NLRs
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by Shae et al. showed, that NLR family X1 (NLRX1), followed by NOD1 and NOD2 were most
conserved among those analyzed, but NLRC3 (NOD3) seemed most divergent [48].
2.2 NOD-like receptor CARD domain containing 3 (NLRC3)
NLRC3 is a member of the NLRC family, a subfamily of the NLRs and was formerly known as
NOD3 and CATERPILLER 16.2 (CLR16.2). The NLRC3 is conserved in vertebrates, from the
zebrafish Danio rerio to Homo sapiens [49]. NLRC3 has been described as a cytosolic receptor of
an unknown substrate, and it was shown to be a negative regulator of T cell function [50]. A recent
study claimed that NLRC3 attenuates Toll-like receptor signaling via modification of the signaling
adaptor TRAF6 and transcription factor nuclear factor κ-light-chain-enhancer of activated B cells
(NFκB) [51].
NLRC3 orthologues have been identified and studied in channel catfish (Ictalurus punctatus).
NLRC3 found in kidney, intestine, spleen, and leukocytes in channel catfish lacked the struc-
tural and characteristic NACHT domain [48]. However, Rajendran et al. in 2011 were able to
detect NLRC3 orthologs in other tissues and identified a truncated version with only four LRRs-
markedly 11 LRRs less than previously identified variants. The expression levels of the truncated
NLRC3 ortholog (named NOD3b) were analyzed in intestine, head kidney, spleen, and liver, and
monitored during intracellular, gram-negative bacterial infection. Levels in intestine and head kid-
ney were significantly down regulated, while up regulated in spleen and liver [52]. The receptor
HmNLR in medical leech (Hirudo medicinalis) shows the highest homology to human NLRC3
and has been connected with neuroimmune functions [53].
2.2.1 Gene organisation
The human NLRC3 gene is located on chromosome 16p13.3. It has 20 exons with the translation
initiation in exon 1, and preceded by a 178 bp 5’UTR.
The murine Nlrc3 is encoded on chromosome 16 (A1;16), and contains 18 exons with the initial
start codon in exon 1 and followed by a 225 bp 5’UTR. The open reading frame is terminated in
exon 18, followed by a 2442 bp 3’UTR. According to predictions a CARD domain is encoded
by exon 2 [54]. Following those predictions a NACHT domain including two Walker B motifs is
encoded by exon 3, the LRRs originate in the exons 5 to 14. The murine knockout variant generated
for the experiments of this thesis contains a deletion of exons 2 and 3, which corresponds to a




Members of the NLR family are characteristically organized by modular domains. At the N-
terminus is an effector binding domain followed by a central NOD domain, and at the C-terminus
is a ligand recognition domain which contains mostly several LRRs. Some members like NOD1
(NLRC1), carry an additional NACHT-associated domain (NAD) [30]. Based on the first, al-
beit partial predicted sequence of NLRC3 in 2002 [55], this protein contains three characteristic
domain motifs. Although there is ongoing discussion about the C-terminal effector domain, the
central NACHT domain for protein oligomerization and the LRR are widely accepted (Fig. 2.3).
Effector domain
Currently the architecture of the NLRC3 effector domain at the N-terminus remains uncertain.
Ting et al. proposed a CARD-NACHT-NAD-LRR structure in 2008, whereas Chen et al. and sev-
eral others published an X-NOD-LRR organization, where X represents a heretofore undefined
domain [27, 30, 56, 57]. Analysis of the gene organization in channel catfish Ictalurus puncta-
tus showed no effector domain, but an additional LRR compared to the human sequence [48].
Neither the human nor the murine sequence stored in NCBI (www.ncbi.nlm.nih.gov) and uniprot
(www.uniprot.org) databases are indicating a CARD domain structure. CARD domains are struc-
turally related to death domains and death effector domains, having a similar size and secondary
structure [58]. A structure based multiple sequence alignment of CARD domains indicated, that
NLRC3 does possess a CARD domain. The authors also indicated that the findings by Ting et
al., the published human cDNA clone of NLRC3, referred to as CLR16.2 included two striking
differences: a point mutation Q41H and a N-terminal truncation of 47 amino acids (aa). These
differences detected by Albrecht et al. may prove to be crucial for the folding and function of the
CARD domain [59]. Thus, due to the discordant identity of the N-terminal sequence, the charac-
terization of the NLRC3 effector domain is of importance to understand its function in downstream
signaling.
Fig. 2.3: Domain structure of NLRC3. The domain structure of NLRC3 can be subdivided in three major motifs- the
N-terminal effector domain, the central NACHT domain capable for oligomerization and the C-terminal LRR respon-
sible for ligand binding. The existence of a CARD or yet to be defined domain at the N-terminus and a NAD domain




It has been proposed that upon recognition of PAMPs by the LRRs, NLR proteins oligomerize via
the NACHT domain leading to the recruitment or activation of downstream target proteins through
its effector domain [29, 60]. The centrally-located NACHT domain is encoded by a single exon
and has been found to be involved in the oligomerization processes in the presence of ATP [61].
However it is still unclear whether it allows for homo- or hetero-oligomers.
Ligand binding domain
The 14 LRRs at the C-terminus of the NLRC3 protein are assigned for binding of ligands. Each
LRR is encoded by one exon. Upon comparison of the similar, horseshoe-shaped structures of
the ligand binding domain LRRs, Istomin et al. concluded, that the specificity of LRRs seems
to depend on surface properties, such as hydrophobicity, charge, and glycosylation sites [62].
The phylogenetic analysis showed that NLRC3 clusters to NLRC1 and NLRC2 and a little more
distant to NLRC4 and CIITA. The same study revealed that NLRC3 contains ten consensus N-
glycosylation sites, which is a markedly higher amount compared to all other NLRCs, with none
to two sites. The hydropathy plot of NLRC3 is similar to NALP3, but no similarities within the
whole NLRC protein group were obvious when considering charge distribution.
Studies indicate that NLRs might be negatively regulated by their LRRs [40]. Thus far, no pre-
diction of putative ligands have been made, but it was hypothesized that LRRs may either bind
ligands/DAMPs or possibly some intermediate molecules [62, 63]. In fact, LRRs are found in a
variety of other proteins and confer different roles, such as ligand binding and general structure.
2.2.3 Protein expression
The human NLRC3 protein is localized in the cytosol and is expressed as four isoforms of different
length due to alternative splicing (Fig. 6.1).
Isoform 1 was chosen as canonical sequence with 1065 aa and of 114.7 kDa size according to
the uniprot database. For the second isoform with 1111 aa and 119.4 kDa markedly differs from
isoform 1 at the initial methionine, which has been replaced by a 47 aa long sequence. Isoform 3
of 761 aa and 83.5 kDa size contains an alternate sequence at aa positions 728 - 761 and is missing
aa from 762 - 1065. The 1037 aa long isoform 4 lacks the canonical aa sequence from 869 - 896.
The latter two isoforms have not been experimentally confirmed yet. All sequences are stored in




In contrast, the murine Nlrc3 is expressed as five murine isoforms although isoforms 3 to 5 are not
experimentally confirmed yet (Fig. 6.1). The sequences are saved under the identifier Q5DU56-X
in the uniprot database. Isoform 1 with 1064 aa and 116 kDa size is regarded as the canonical
sequence. Isoform 2 with 726 aa and 80.8 kDa size differs at three sequences with respect to
isoform 1, where aa sequences 1 - 27 and 643 - 688 are altered and 689 - 1064 are missing.
Isoform three is truncated to 397 aa and 41.7 kDa where the aa sequence from 1 - 677 is missing
and altered from 668 - 670. Isoform 4 is equally truncated to 312 aa and 32.9 kDa size and aa 679
has been changed from D to E and the isoform lacks the canonical sequence representing aa 980 -
1064. The last known isoform of 239 aa and 25.5 kDa lacks the aa sequence and 876 - 1064, 1 -
636 and has two substitutions 637 - 641 and 841 - 875 respectively. The aa sequence 876 - 1064
is missing compared to the canonical isoform.
The canonical sequence is conserved in human, chimpanzee, dog, cow, mouse, rat, and zebrafish.
The homology between mouse and human canonical sequences is 80 %. Representative diagrams
of the isoforms are shown in the chapter Supplement (chapter 6).
2.2.4 Function of NLRC3
It has been stated that NLRC3 is a negative regulator of T cell function and a proposed negative
regulatory role via the NFκB pathway [50]. Results from a previously performed Y2H screen
indicated an interaction of NLRC3 with the mitochondrial protein IMMT. Additionally, the in-
volvement of several NLRs in pathways finally leading to apoptosis, either in an enhancing or in
an inducing way, has been published [64, 65, 66, 67]. Recent studies indicated, that NLRs may ex-
hibit functions beyond the mere recognition of pathogens, such as maintaining tissue homeostasis
and apoptosis [34]. With regard to methodical findings Ling et al. stated, that the overexpression
of NLRC3 results in non-specific post-transcriptional inhibition of luciferase reporter assays [68].
2.3 Mitochondria
Mitochondria are one of the most important cell organelles. They are enclosed by two membrane
layers, referred to simply as the outer and inner mitochondrial membranes. The former membrane
structure is mainly responsible for selective transport. In contrast, the inner mitochondrial mem-
brane forms a highly dynamic and extended network, forming cisterna structures in either a tubular
or cristae way. This membrane is similar to bacterial membrane, which is hypothesized to be from
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an endosymbiontic event in which a double-membrane proteobacterium was engulfed by a precur-
sor eukaryote. By this event the eukaryote cell gained the capability of aerobic respiration [69].
The mitochondrial proteome consists of approximately 1513 proteins, of which 13 are encoded by
the mtDNA and roughly 1500 by the nuclear DNA [70]. The metabolic functions of mitochondria
are diverse and the list of processes involving mitochondria is still growing. One of the central fea-
tures of the mitochondria is the electron transport chain, which occurs along its inner membrane
and generates adenosine triphosphate and NADPH.
In fact, some complexes of the electron transport chain are composed of mtDNA- and nuclear-
encoded proteins. Thus, any disturbance of mtDNA or its encoded proteins would lead to mito-
chondrial stress as the nuclear encoded proteins would still be imported. Lacking a mitochondrial
partner the proteins would fail to assemble appropriately, for instance in stoichiometric correct
complexes. A strong control and regulatory mechanism, such as the mitochondrial unfolded pro-
tein response (mtUPR) evolved to detect specific mis- or unfolded mitochondrial proteins and to
react upon those. A similar system is well known for the endoplasmatic reticulum, called erUPR,
but the perturbations that induce mtUPR do not induce erUPR [71]. Recent studies show, that
mitochondria are also involved in cell signaling for cell death and innate immunity by serving as
hubs for signaling interactions and regulating intracellular signaling molecules, such as ROS and
Ca2+ [72]. ROS have been shown to modulate the NFκB pathway [73]. They are either generated
by complex I or III of the electron transport chain or by cellular members of the NOX/DUOX fam-
ily [74, 75, 76, 77]. Additionally, mitochondria are able to release Ca2+, cytochrome c, and, after
lysis, mtDNA, which might be regarded as DAMPs that trigger downstream signaling cascades.
The importance of mitochondria and its maintenance is further underlined by the fact that cells
possess a system to dispose dysfunctional mitochondria. This lysosome dependent degradation of
mitochondria is named mitophagy [78].
2.3.1 Inner mitochondrial membrane protein (IMMT)/Mitofilin
The inner mitochondrial membrane protein also referred to as Mitofilin is a 85 kDa mitochondrial
protein. IMMT is anchored in the inner mitochondrial membrane by an N-terminal transmembrane
segment, a large hydrophilic part, which contains predicted coiled-coil regions and a conserved C-
terminal domain. The protein is exposed to the intermembrane space [79].
Downregulation of IMMT resulted in decreased cell proliferation and increased apoptosis, which
indicates mitochondrial dysfunction. Although the mitochondrial fusion and fission was normal,
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the inner membrane was disorganized and failed to form cristae. Amorphous cross-linked mem-
brane stacks were observed instead [80]. The C-terminal domain, which is required for the ap-
propriate cristae formation is also an essential linker to high-molecular weight complexes [81].
IMMT is an essential part of the mitochondrial inner membrane organizing system, a large protein
complex of crucial importance for membrane architecture [82, 83, 84].
Additionally, IMMT has been shown to be involved in protein transport. The inner mitochondrial
membrane consists of two morphologically distinc regions: the inner boundary membrane, which
is in close proximity to the outer membrane, and a large tubular invagination of the cristae mem-
branes [85, 86]. Studies have indicated that the inner boundary membrane and cristae domains are
distinct subcompartments of the inner membrane, since these exhibit asymmetric protein distribu-
tion [87, 88]. Studies using a Yeast-2-hybrid screen indicated that two major components of the
protein translocase of the outer membrane (TOM) are potential interaction partners of IMMT - the
channel forming TOM40 and the central receptor TOM22 [89, 90, 91]. IMMT seemed to interact
with several import and organizing pathways, since a knockout leads to various deficiencies. This
indicates that IMMT is a central regulator of the translocation and mitochondrial organization [91].
Beside the translocation through the outer membrane via TOM, first indications appear for a lat-
eral release of proteins by TOM. It has been hypothesized that some sequences promote a lateral
release from the TOM complex. A lateral transfer has been shown experimentally, still lacking
a full mechanistically understanding [92]. A protein transport by TOM might prove crucial for
interactions between cytosolic and mitochondrial proteins, such as IMMT. In summary is IMMT
an important protein for mitochondrial structure and protein import.
2.4 Cytokines and chemokines
As it becomes clear, that NLRC3 is involved in immune related signaling, it is necessary to
introduce cytokines and chemokines as central members of the downstream immune response.
Cytokines are secreted proteins with various functions that determine the nature of an immune
response. By binding to their respective receptors of the innate immune system, cytokines can
then trigger downstream signal cascades resulting in the activation of transcription factors, such
as NFκB, activator protein 1 (AP-1), and protein53 (p53). These transcription factors themselves
enable the production of cytokines. The analysis of the exact function of each cytokine is compli-
cated due to the complex interplay between signaling cascades occurring within a cell, as well as
with different states of cellular development and phase of the immune response. First coined in
13
INTRODUCTION
1979, interleukins (IL) are a diverse group of cytokines mostly perceived by cell surface receptors
[93]. In contrast to hormones they act generally in a para- or autocrine manner. Currently, there
are 55 known IL and IL-related genes [94]. Further characterization of IL-genes via sequence
analysis is hindered by the poor amino acid conservation. A study has shown that seven out of
the 25 most divergent genes were cytokines [94, 95]. Cytokines signal mostly via the JAK/STAT
pathways, which involve a phosphorylation by a cytosolic tyrosine kinase, followed by dimer-
ization and nuclear translocation. A variety of STAT proteins enable a cytokine-specific reaction
[96, 97, 98]. The impact of cytokines on the NFκB pathway is further described under section 2.5.
The cytokines listed in the following are involved in known immune responses, and were analyzed
in NLRC3 related experiments:
The IL-1 cytokine family contains a group of eleven cytokines which share a conserved β-trefoil
structure of 12 packed β-sheets [99]. The major function of IL-1 is to activate T lymphocytes by
enhancing the production of IL-2 [100]. IL-1 is considered to be a pro-inflammatory interleukin, its
absence is marked by a diminished immune response. The work presented here is focused on IL-
1β. IL-1β is inducible by LPS stimuli via the inflammasome. The induced precursor protein has
to be cleaved by caspase-1 to become the active form primarily secreted by stimulated monocytes
and macrophages [101, 102].
IL-1β has already been described in functional context with members of the NLR group (NLRC4,
NLRP3) as inflammasome assembly activates pro-caspase-1 which can process IL-1β and IL-18
[33].
IL-2 is one of the first cytokines identified and characterized [103] featuring a four-helix bundle
motif [94]. It has been described as a mediator for T cell homeostasis and differentiation [104].
IL-2 is neither strictly pro- nor anti-inflammatory as it is involved in the production of various
cytokines, such as interferon-γ and IL-4 [105]. IL-2 transcription can be abrogated in NOD2- and
NLRP3-deficient dendritic cells by stimulation with monosodium urate [106].
IL-6 is a monomeric protein member of a group of long-chain class 1 helical cytokines. It binds
to the dimeric receptor IL6Rα and associated with another dimeric receptor IL6ST (gp130) in a
cooperative manner, forming a special hexameric signaling complex [94]. Recent studies indicate,
that IL-6 has a double sided effect on inflammatory pathways. Depending on its targeted receptor
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one has to distinguish the classic signaling via a membrane bound receptor and the trans-signaling
via a soluble receptor. Latter seems to promote pro-inflammatory signaling, while the classic way
seems to support anti-inflammatory processes [107]. IL-6 is mainly produced by mononuclear
phagocytic cells, but is also produced by T and B lymphocytes, and bone marrow cells [108]. IL-6
can be regarded as a key player during the early state of immune response through its involvement
in the T cell activation and differentiation [109]. The presence of LPS, an unique feature of gram-
negative bacteria, is a known inducer of NLR mediated IL-6 activation [61].
IL-10 was first described as an inhibitor of T helper 1 lymphocyte (TH1) cytokine expression and
is one of the best studied anti-inflammatory interleukines [110, 111]. Structurally, IL-10 is char-
acterized by six α-helices in anti-parallel conformation [112]. The anti-inflammatory function of
IL-10 has been described for monocytes and dendritic cells in its ability to limit cytokine and
chemokine production activated by TLR agonists, such as LPS and bacterial lipoproteins. Upon
LPS stimulation of monocytes IL-10 forms a homodimer resulting in a reduction of CD40 ligand
and activation of MAPK pathways [113, 114, 115]. IL-10 was able to block NFκB activation in
response to IL-1β and was shown to reduce IκB degradation [113, 116]. STAT3 mediated sig-
naling of IL-10 plays a major role in dampening the TNFα induced inflammatory events [117].
Nevertheless, IL-10 may react differently depending on stimulus level and cell type [118].
IL-12 is an interleukin with a bundle of four α-helices, which is encoded by the genes IL-12A
(p35) and IL-12B (p40) [119]. Its structure is comparable to IL-6. IL-12 is mostly produced by
dendritic cells, but not in B cells [120, 121]. It is important for T cell differentiation, is able to
recruit natural killer cells, and plays a major role in the activation of interferon-γ production via
STAT pathway [100, 122, 123]. Furthermore it is discussed as anti-tumor agent [124, 125].
Tumor necrosis factor α (TNFα) is a cytokine produced by a variety of cells, including mononu-
clear cells, natural killer cells, and lymphocytes [126]. TNFα is a homotrimeric transmembrane
protein, which is processed by the TNFα-converting enzyme. The soluble form of TNFα is cleaved
and mediates its biological activities through binding to types 1 and 2 TNF receptors (TNF-R1 and
-R2) [127, 128]. TNFα secretion can be induced by peptidoglycans, lipopolysaccharides, and bac-
terial DNA CpG motifs that are bound by TLRs [129, 130]. It signals via the TNF receptor, more
precisely, by either a TNF-associated factor or a death domain, which is a member of the same
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protein superfamily as CARD [131]. The main immune function of TNFα lies in coordinating a
concerted cellular immune response of the up to 109 different B and T lymphocytes in a single
host organism [129]. TNFα is a potent inducer of cell death and generally a pro-inflammatory
cytokine. IL-10 induced TNFα expression has been shown to destabilize inflammatory gene tran-
scripts [132].
One group of cytokines are the small chemokines responsible for attracting immune cells to ap-
propriate sites via chemotaxis. Chemokines were first described in 1977 and characterization
has revealed over 50 known chemokines with leukocyte chemotactic and cytokine-like activi-
ties [133, 134]. In contrast to cytokines and interleukins which utilize cytosolic tyrosine kinases-
mediated signaling, chemokines dependent on G proteins [135]. However, the structural homology
between the murine and human form is matter of debate [136].
The murine IL-8 is named CXCL1, after a specific CXC motif and was formerly known as KC
[137]. The dimer is composed of a six-stranded β-sheet and two parallel α-helices [138]. IL-8
is produced in mast cells, macrophages, and endothelial cells [139, 140, 141]. Human IL-8 is
inducible by several stimuli, including oxidative stress, LPS, and TNFα [142, 143]. IL-8 was
found to be increased in patients with an active ulcerative colitis [144].
2.5 NFκB
As mentioned above, NLRC3 was proposed to have a negative regulatory function on the NFκB
(nuclear factor κ-light-chain-enhancer of activated B cells) pathway. NFκB is one of the best
studied and nearly ubiquitously expressed transcription factor of mammalian cells. It was first
described in 1986 [145]. Mammalian cells possess five NFκB family members: RelA (p65), RelB,
c-Rel, as well as the two transcriptional inactive subunits NFκB1 (p50) and NFκB2 (p52) or their
respective precursor proteins p100 and p105 [146, 147].
It has been widely accepted that NFκB is a key regulator in cellular development and response
to certain stimuli [148] and that these two processes are considered to be strongly interconnected.
The basis of the work presented in this thesis is the involvement of NFκB in response to stimuli
and NLRC3 modulation. A multitude of signaling pathways result in the regulation of NFκB,
implying a complex regulatory system to ensure, that only the aimed effect is gained. Beside a
huge variety of stimuli TNFα and ROS have been reviewed to activate NFκB [149]. Additionally,
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NFκB is a central hub for most interleukins connected to inflammatory responses.
Two general pathways have been identified in NFκB-mediated signaling. In the canonical path-
way NFκB is bound to its inhibitor IκBα in the cytoplasm. Upon stimulation the IκB kinase
(IKK) complex consisting of IKK1/IKKα, IKK2/IKKβ, and the regulatory subunit IKKγ (NFκB
essential modulator/NEMO) phosphorylates the inhibitory IκB proteins. The phosphorylation is
followed by a course of molecular events involving polyubiquitination of IκB, its proteosomal
degradation, and resulting in an accumulation of active NFκB. The p50-p65 heterodimer of NFκB
translocates into the nucleus, whereupon it binds to the DNA allowing for transcription to initiate.
The non-canonical way is mediated via the phosphorylation of IKKα, which phosphorylates a
p100-RelB heterodimer. The phosphorylated precursor protein p100 undergoes ubiquitination fol-
lowed by proteasomal processing to p52. It then translocates into the nucleus, binds to DNA, and
initiates transcription [150, 151]. The NFκB response to stimuli, such as LPS, is detectable within
30 minutes [145]. The impact of the NFκB pathway and its constituents have been excessively
studied in mice, including all major transgenic overexpressions or knockouts [152, 153] giving a
thorough basis for further analysis.
2.6 Inflammatory bowel diseases
Ulcerative colitis and Crohn’s disease are subsumed as inflammatory bowel diseases (IBD). IBD
as a complex disease is characterized by acute exacerbations followed by remissions. It may dis-
play incidence rates of up to 16.8 (cases per 100000 inhabitants per year) depending on the study
type and geographical location [154]. The cause of the disease is not fully understood, but sev-
eral circumstances, such as environmental factors and genetic susceptibility loci seem to play an
important role [155, 156]. Nevertheless are the symptoms well reflected by those described for
induced murine colitis [157]. Knockout mice develop colitis resembling the human pathologies,
such as ulcerative colitis (IL-2-/- [158]) and Crohn’s disease (IL-10-/- [159]).
2.6.1 Dextran sulfate sodium induced colitis as mouse model for IBD
Dextran Sulfate Sodium (DSS) is a negatively charged long chain polymer of sulfated glucose.
DSS has been described to potently induce colitis, leading to diarrhea, gross rectal bleeding, and
weight loss in mice [160]. The molecular mechanisms underlying the DSS-induced colitis are not
fully understood yet, but DSS is considered to effect directly the intestinal epithelial cells of the
crypts disintegrating the mucosa. It was shown, that only the whole polymer is capable to induce
17
INTRODUCTION
the colitis [161]. Additionally, disruption of cellular functions and inhibition of ribonucleases have
been reported in association with DSS treatment [162, 163]. Laroui et al. proposed a negative effect
of DSS on cell monolayer resistance, and showed that dextran-loaded nanoparticles were able to
induce colitis [161]. DSS-induced colitis is high reproducible and provides a inducible mouse-
model without major players of the adaptive immune system [164]. Nevertheless, manipulations
of e.g. γδ T cells are capable of an exacerbation of the disease [165]. In general an oral DSS
administration (1 - 10 % solved in drinking water) leads to a disruption of the colonic epithelia,
exposing the lamina propria to the gut bacteria [160, 166, 167, 168]. Murine colitis is an useful
model for human ulcerative colitis, resembling the penetration of the inner colon mucus layer,
which should be impenetrable [7].
2.7 Aim of this work
The aim of this study was the functional characterization of the NOD like receptor NLRC3. Only
few studies have investigated the function of NLRC3 yet. To achieve a better understanding of the
putative immune receptor NLRC3 following major tasks were assessed:
• Describing the NLRC3 impact on NFκB signaling via dual luciferase assays and quantifying
the interleukin level as the backbone of a functional characterization of NLRC3.
• Analyzing the molecular interaction of NLRC3 and Mitofilin and testing a potential impact
of NLRC3 on mitochondrial integrity and apoptosis.
• Establishing and characterization of a Nlrc3-/- mouse strain.
The experiments and results presented in this thesis are associated with the innate immune system,
and therefore a focus will be set to the respective processes and signaling.
These questions and experimental setups aim at a more detailed understanding of the hitherto
largely uncharacterized putative immune receptor NLRC3. Relating experimental data to clinical
relevant diseases, enhances the importance of a close analysis of NLRC3. A broader analysis of its




3 Material and Methods
3.1 Materials and reagents
3.1.1 Plasmids and bacteria
The following tables are documenting the plasmids and Gateway vectors used for this project. The
plasmid backbones, transfer vectors, and negative controls are given in Tab. 3.1 and the vectors
cloned via the Gateway system are enlisted in Tab. 3.2. The One shot Top 10 bacteria used for
transformation are further specified in Tab. 3.3.
Tab. 3.1: Basic constructs. The basic constructs were used as backbones for newly constructed vectors, as negative
controls or for luciferase assay purposes. All constructs were suitable for expression in mammalian cells.
name description supplier
pCDNA3.1 vector backbone Life Technologies
pDONR221 Gateway cloning vector with M13 sequencing site and
kanamycin selection marker
Life Technologies
pcDNA-DEST53 Gateway cloning vector with green fluorescent protein
gene for N-terminal fusion
Life Technologies
pCEV3.1 flag vector Life Technologies
pNFκB-Luc firefly luciferase under control of NFκB promoter Clontech
pRL-TK Renilla luciferase under control of thymidin kinase
promoter
Promega
Tab. 3.2: Gateway cloned vectors, carrying an AmpR. The basic constructs were used as backbone for specific
vectors.
name description
pDEST-NLRC3 NLRC3 with N-terminal GFP
pCEV-NLRC3 NLRC3 with 3 N-terminal flag-tags
pCEV-IMMT IMMT with 3 N-terminal flag-tags
pCEV-NLRC3-CARD NLRC3 CARD domain with 3 N-terminal flag-tags
pCEV-NLRC3-NACHT NLRC3 NACHT domain with 3 N-terminal flag-tags
pCEV-NLRC3-LRR NLRC3 LRR domain with 3 N-terminal flag-tags
3.1.2 Cell lines and media
Following media were used to maintain, cultivate, and transfect primary and secondary cell cul-
ture. Media were either used pure (indicated by medium-/-) or supplemented with 10 % fetal calf
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Tab. 3.3: Bacteria. TOP10 bacteria were used for all transformations. The exact specification is given.
name description supplier
Top10 F-mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacX74
recA1 araD139 ∆(araleu)7697 galU galK rpsL (StrR) endA1
nupG
Life Technologies
serum (FCS), glutamine, and 1 % penicillin/streptomycin (pen/strep) (indicated by medium+/+). All
basic media were bought from PAA Laboratories GmbH (Pasching, Germany). Tab. 3.4 summa-
rizes which medium was used while cultivating the respective cell line. Additionally, OPTI-MEM
(Invitrogen/Life Technologies, Darmstadt, Germany) was used for siRNA transfection.
Tab. 3.4: Cell lines. Cell lines used are enlisted with their respective media and reference. Some media were modified
to fit specific needs and are indicated as sup(plemented). Basic media are Minimum Essential Medium (MEM), Dul-
becco’s Modified Eagle Medium (DMEM), Roswell Park Memorial Institute Medium (RPMI), and Mouse Macrophage
Medium (MMM). References are given with respect to the accession number (ACC) of the Leibniz Institute DSMZ -
German Collection of Microorganisms and Cell Cultures (DSMZ) and literature (lit.). ModeK cells were kindly pro-
vided by Prof. Dr. Dirk Haller, Munich. Media were supplemented with FCS, glutamine and pen/strep. The bone
marrow derived macrophages (BMDM) medium was additionally enriched with amphotericin and Macrophage colony-
stimulating factor.
name description medium DSMZ lit.
CaCo-2 human colon carcinoma cells MEM+/+ ACC-169 [169]
HEK-293 human embryo kidney cells DMEM+/+ ACC-305 [170]
HeLa human cervix carcinoma cells MEM+/+ ACC-57 [171]
HT-29 human colon adenocarcinoma cells DMEM+/+ ACC-299 [172]
Jurkat human T cell leukaemia RPMI+/+ ACC-282 [173]
THP-1 human acute monocytic leukaemia RPMI+/+ ACC-16 [174]
ModeK murine duodenum cells sup. DMEM+/+ [175]
RAW 264.7 murine leukemic monocyte macrophage sup. DMEM+/+ [176]
BMDM murine bone marrow MMM+/+




Oligonucleotides are short, single stranded DNA molecules which were used for end-point PCRs
and sequencing approaches. The name used in the documentation, the sequence, expected ampli-
con size, and melting temperature are given in Tab. 3.5.
Tab. 3.5: Oligonucleotides. The oligonucleotides were used for end-point PCRs and full length sequencing. Amplicon
length were non applicable in sequencing approaches. The length may vary due to different inserts or due to the nature
of templates (cDNA/gDNA).
Oligo name sequence (5’→ 3’) amplicon Tm
size [bp] [°C]
747 pDONR221-M13fwd GTAAAACGACGGCCAG variable 60
746 pDONR221-M13rev GCCAGGAAACAGCTATGACC variable 60
Ros1 Nod3_KO_PCR#3_F GACTTCTCCCTGTGTCTCAGCCAGC 3048 63
Ros1 Nod3_KO_PCR#3_R GCCCTTCAATGCCAACAGTTCTCC 3048 63
ROS1(Nod3)_KO_PCR#2_F AGAGCCAGGGAAGCTGAGAGAAGTAGC 2309/2480 63
4804
ROS1(Nod3)_KO_PCR#2_R CATGACCCCAAGCGTTGCTTACATC 4804 63
m10Nlrc3 f GAAGAGCTGAGGGGCTGCAGTGA 300 60
m10Nlrc3 r ATGTTGTCTCCTTCCTGCCATGGTGGC 300 60
β-Actin f GATCGGTGGCTCCATCCTGGC 130 64
β-Actin r CGCAGCTCAGTAACAGTCCGCC 130 64
mGAPDH f CCGGGGCTGGCATTGCTCTCA 160/279 64
mGAPDH r CTTGCTCAGTGTCCTTGCTGGGG 160/279 64
608_IMMT_1fwd CTGCGGGCCTGTCAGTTATC N/A 55
609_IMMT_2fwd TACTCAGACAAACTCTTCGA N/A 55
610_IMMT_3fwd GATACTCCAGCTTCAGCAAC N/A 55
611_IMMT_4fwd GAAGTTGCAGCTCGCCTTGC N/A 55
612_IMMT_5fwd TTGAAGGAACGCAGAAAGGC N/A 55
613_IMMT_6fwd CTGGTGGTCCAAGCTCGGGA N/A 55
614_IMMT_7fwd GAAAAGCGGGCATTTGACTC N/A 55
615_IMMT_8fwd GAATTACAATTTCGTCGTCT N/A 55
616_IMMT_9fwd GCCAACTGTTCTGATAATGA N/A 55
617_IMMT_10fwd TGCCCTGAGGATATAAACAC N/A 55
618_IMMT_11fwd GCACAGGACTGGCTGAAGGA N/A 55
619_IMMT_1rev CCCAGAGCTGCCTGAAGTAG N/A 55
3.1.4 Antibodies and dyes
For Western blot applications the antibodies were diluted in 5 % skimmed milk powder. All other
applications were carried out according to the respective protocol. The antibodies used for West-
ern blot applications are enlisted in Tab. 3.6. Suitable secondary antibodies were purchased from
Biomol (Hamburg, Germany) and diluted 1:2000. Cover slip staining were realized utilizing chem-
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ical dyes and antibodies. The antibodies listed in Tab. 3.6 were used according Tab. 3.7.
Tab. 3.6: Primary antibodies. Western blots were incubated with unlabeled primary antibodies as listed below. The
incubation time varied according to the application between one and 72 hours. Detection was enabled by the application
of species specific HRP-coupled secondary antibodies. Abbreviation used: clon: conality; m: mono; p: poly.
name origin clon WB-dilution target supplier catalog
α-β-Actin mouse m 1:10000 human/mouse Sigma-Aldrich A-5441
α-IMMT mouse p 1:500 human Abcam ab48139
α-NLRC3 rabbit p 1:250-1:500 human Abcam ab77817
α-β-Tubulin rabbit m 1:1000 human Cell signaling Kit 4753
α-β-flag mouse m 1:1000 human Stratagene 200472
α-TRAF6 rabbit m 1:1000 human/mouse Abcam ab33915
α-IgG rabbit N/A varied N/A Santa-Cruz sc-2027
To visualize cellular localization several dyes and antibodies were applied according to Tab. 3.7.
Tab. 3.7: Antibodies and dyes. Different dyes and antibodies were applied to the cells. Primary antibodies were
detected by secondary antibodies, which were coupled to AlexaFluor fluorochromes purchased from Invitrogen. The
respective secondary antibodies are indicated in the experiments. Nuclear staining was performed by DAPI or Syto-45,
depending on choice of microscope.
antibody/dye dilution incubation time supplier catalog
Mitotracker 1:20000 30 min Life Technologies M-7512
DAPI 1:100000 10 min Sigma-Aldrich D9564
Syto-45 1:100000 10 min Life Technologies S11356
α-IMMT 1:500 60 min Abcam ab48139
α-NLRC3 1:500 60 min Abcam ab77817
α-IgG equal to α-NLRC3 60 min Santa-Cruz sc-2027
α-flag 1:1000 60 min Stratagene 200472
Several antibodies were tested for histological staining. The successfully tested antibodies are
shown in Tab. 3.8. The antibodies against NLRC3 and IMMT failed in histological approaches.
Tab. 3.8: Antibodies for histological staining. Histological staining were conducted according to the Vectastain Elite
staining protocol (Vector Laboratories, Burlingame, CA, USA). Primary antibodies not included in the kit are listed
below.
name origin clon dilution target supplier catalog
α-TRAF6 rabbit m 1:50-1:100 human/mouse Abcam ab33915
α-NFκB p65 XP rabbit m 1:25-1:50 human/mouse Cell signaling 8242
3.1.5 Buffer
Buffers were composed according to the list given in Tab. 3.9.
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Tab. 3.9: Buffer list. The most important and frequently used buffers and their composition are listed. Buffers were
composited ad 1 liter H2O.
buffer composition
anode buffer 1 30 mM Tris, 20 % (v/v) CH3OH
anode buffer 2 300 mM Tris, 20 % (v/v) CH3OH
cathode buffer 25 mM Tris, 20 % (v/v) CH3OH, 40 mM NH2(CH2)5COOH
cell fractionation 1 10 mM C8H18N2O4S, 10 mM KCl, 1.5 mM MgCl2, 10 mM NaF
cell fractionation 2 20 mM C8H18N2O4S, 420 mM NaCl, 1.5 mM MgCl2,
0.2 mM C10H16N2O8, 25 % glycerol, 10 mM NaF
DLB 20 mM Tris/HCl (pH 7.4), 2 % (w/v) SDS
DNA loading dye 50 % (v/v) Glycerol, 0.1 % (w/v) C19H10Br4O5S,
0.1 % (w/v) C25H27N2NaO6S2
ELISA assay 8 g/l NaCl, 0.2 g/l KCl, 1.13 g/l Na2HPO4, 0.2 g/l KH2PO4, pH 7.4
ELISA stop 1.8 N H2SO4
ELISA wash 9 g/l NaCl, 0.1 % (v/v) Tween20
LB Agar 10 g/l tryptone, 5 g/l yeast extract, 5 g/l NaCl, 15 g/l agar agar
LB Medium 10 g/l tryptone, 5 g/l yeast extract, 5 g/l NaCl
loading gel 0.5 M Tris/HCl (pH 6.8), 0.4 % (w/v) SDS
PBS 8 g/l NaCl, 0.2 g/l KCl, 1.56 g/l Na2HPO4, 0.24 g/l KH2PO4, pH 7.4
RIPA 150 mM NaCl, 1 % NP40, 0.5 % C24H40O4, 0.1 % SDS, 50 mM Tris, pH
8.0
separation gel 1.5 M Tris/HCl (pH 8.8), 0.4 % (w/v) SDS
SOC 2 % (w/v) tryptone, 0.5 % (w/v) yeast extract, 10 mM NaCl, 2.5 mM KCl,
10 mM MgCl2, 10 mM MgSO4
Stripping buffer 62.5 mM Tris (pH 6.8), 2 % SDS, HSCH2CH2OH (400 µl per 50 ml)
TAE (25x) 1 M Tris/HCl (pH 8.0), 25 mM EDTA, 500 mM CH3CO2H
TE 10 mM Tris/HCl, 1 mM EDTA
TTBS 20 mM Tris, 137 mM NaCl, 0.1 % (v/v) Tween20
3.2 Methods of molecular biology
3.2.1 Polymerase chain reaction
A polymerase chain reaction (PCR) aims to amplify short sequences of given cDNA or gDNA by
the use of specific oligomers, Taq polymerase, dNTPs, and a supplemented buffer.
Oligomers
Oligomers used for PCR based analysis are given in Tab. 3.5. Oligomers were ordered from Mi-
crosynth (Balgach, Switzerland). The lyophilized oligomers were resolved in deionized water to
100 µM. The concentration of the working dilution was 10 µM for PCR, 5 µM for plasmid se-
quencing and 3.3 µM for PCR-product sequencing. Elongation time was estimated as 30 s per 500




Two different Taq-systems were used for end point PCRs. Genotyping of mice was based on the
DREAM-Taq system (Thermo Scientific, Bremen, Germany), all other PCRs relied on the GoTaq
system (Promega, Mannheim, Germany). The respective mastermix was composed according to
manufacturer’s guidelines. PCR was performed in 96 well Thermocyclers, Tm is given in Tab. 3.5.
An overview of PCR mastermix composition and the cycling procedure is given in Tab. 3.10.
Tab. 3.10: Standard PCR conditions. The composition of a standardized mastermix is given in A. The general se-
quence of a PCR protocol is shown in B. The steps indicated in bold were repeated 35 times.
A mixture final conc. B temp. [°C] t [s] cycles
H2O 12.8 µl 95 240 1
5x buffer 4 µl 1x 95 30
oligos (fwd & rev) 0.5 µl 0.5 µM Tm 30 35
dNTPs 0.5 µl 0.2 mM each 72 60 s/kb
GoTaq 0.2 µl 1 U 72 240 1
template (cDNA) 2 µl 10 break
Amplicons were checked for their size by agarose gel electrophoresis. Agarose gels were poured
as 1 % gels in 0.5x TBE buffer (Rotiphorese TBE-Puffer, Carl Roth, Karlsruhe, Germany). Sam-
ples were loaded onto the gel and exposed to 400 mA, 130 V for 30 minutes. Size of amplicons
was gained by comparing to SmartLadder (Eurogentec, Cologne, Germany).
Real-time quantitative qRT-PCR/TaqMan
The cDNA was adjusted to 2 ng/µl and replenished with water to 5 µl. After adding 4.5 µl Gene-
Expression Mastermix and 0.5 µl Gene Expression TaqMan Assay (Life Technologies) the cycler
program according to Tab. 3.11 was applied on a 7900 HT Fast Real-Time PCR System (Applied
Biosystems/Life Technologies Corporation, Carlsbad, USA).
All results were normalized to the respective β-Actin housekeeper value. TaqMan assays are
indicated either in ∆Ct or in foldchange. Foldchanges relate all data to a reference, while ∆Ct
are values more variable between experiments. A summary of experiments, as shown in the IL-
screening of bone marrow derived macrophages (Fig. 4.21) has to be done in foldchanges to relate
the experiments correctly.
Sanger sequencing
To determine the exact sequence of nucleotides in a plasmid or amplicon the dye-terminator se-
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Tab. 3.11: Cycler program and probe identification for qRT-PCR. The general PCR protocol is given in A. The
probe identifier and supplier are given in B.
A temp. [°C] t [s] cycles B gene catalog supplier
50 120 Nlrc3 4331182 Life Technologies
95 600 IL-1β 01336189 Life Technologies
95 15 IL-2 4331182 Life Technologies
60 60 45 IL-6 99999064 Life Technologies
IL-10 00439614 Life Technologies
IL-12 00434174 Life Technologies
CXCL1 00433859 Life Technologies
quencing technique was applied. The method was based on the sequence method originally de-
scribed by Sanger et al. [177]. In principle a template (amplicon, plasmid) was provided with
a specific oligomer, DNA polymerase, supplemented buffer, and fluorescent labeled dideoxynu-
cleotides (ddNTPs) as shown in Tab. 3.12. In the following PCR reaction the ddNTPs were incor-
porated into the amplicons resulting in a termination of the amplification. As the ddNTPs were
labeled with a fluorescent dye specific for a nucleobase and the incorporation occurred randomly
it resulted in amplicons of different length. Separating the amplicons by electrophoresis through
thin capillaries and detecting their fluorescence by a laser enables the reading of the sequence.
Tab. 3.12: Sanger sequencing. A The composition of PCR mixes are given for plasmid or PCR amplicon templates. B
The PCR program was used for both types of template. BigDye v1.1 was purchased from Life Technologies.
A plasmid PCR amplicon B temp. [°C] t [s] cycles
PCR-H2O 4 µl 4.8 µl 96 60 1
BigDye v1.1 1.5 µl 0.35 µl 96 10
single primer 1 µl (5 pmol/µl) 1 µl 50 5 25-30
5x SB buffer 1 µl 1.85 µl 60 240
template min. 300 ng/2 µl 2 µl 10 break 1
Genotyping
Genotyping was performed by interpreting the results of two different PCRs. Combining the re-
sults of both PCRs was a safe system to distinguish between homozygote wildtype (Nlrc3+/+, WT)
or knockout (Nlrc3-/-, KO) animals as well as heterozygote mice (Nlrc3+/-) as used during the
back crossing events. An overview for the genotyping results is given in Tab. 3.13 and a generic
genotyping result is shown in Fig. 3.1.
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Fig. 3.1: Murine Nlrc3 genotyping. The gDNA was isolated from
mouse ear clips or tail biopsies via Qiagen DNeasy kit and PCR was
performed using Qiagen Dream-Taq, each according to manufacturer’s
protocols. Samples were loaded on a 1 % agarose gel and separated at
400 mA, 100 V for 45 minutes. Picture of gel with inverted gray scale.
Tab. 3.13: Amplicon length for murine
genotyping PCR. PCR #2 Depending on
the genotype bands were expected at 4804
bp (WT), 2309 bp, and 2480 bp (het-
erozygote) or 2309 bp (KO). PCR #3 A
band at 2048 bp is expected for WT and
heterozygote samples, while KO sample
do not show a band.
amplicon length [bp] genotype
PCR #2 PCR #3
4804 3048 +/+ (WT)
2309+ 3048 +/-
2480
2309 none -/- (KO)
3.2.2 Gateway cloning
In order to overexpress NLRC3, IMMT, or single domains of NLRC3, in different experimental
setups or to visualize its location, several inserts were cloned into a vector system carrying either
a green fluorescent protein (GFP) or a flag-tag (Tab. 3.2). The cloning strategy was based upon the
Gateway system (Life Technologies). Gateway cloning relied on recombination by λ enzymes.
First the inserts had to be generated. Therefore specific oligomers were generated which were
extended by a 25 bp sequence giving an attB-recombination site. A PCR reaction was carried out,
amplifying the target sequence, and prolonging it with the attB-recombination site. The amplicon
was analyzed by gel electrophoresis and Sanger sequencing.
The successive cloning was subdivided in two cloning steps. First the amplicon had to be cloned
into a donor vector (pDONR221). The components of the BP Clonase II reaction are given in Tab.
3.14 A. The formulation was incubated at 16°C overnight, followed by a Proteinase K treatment
(1 µl, 37°C, 15 minutes) to digest the phage enzymes. The ligated plasmids were transformed
into TOP10 Escherichia coli (Invitrogen/Life Technologies). For transformation one shot TOP10
cells were thawed on ice. 15 µl of the Escherichia coli suspension were supplemented with 1 µl
Proteinase K treated ligation mix and incubated for 30 minutes on ice. After applying a heat shock
(42°C, 30 s) the cells were incubated in 250 µl SOC-Medium (Life Technologies) at 37°C/300 rpm
for at least 1 hour before they were plated on kanamycin supplemented agar plates and incubated
overnight at 37°C. Single clones were picked after 24 hours and verified by PCR using vector
binding M13 oligomers. Positive clones were transferred to a master plate and stored at 4°C.
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Tab. 3.14: Gateway cloning mixtures. The composition of the A BP Clonase II and the subsequent B LR Clonase is
given.
A BP Clonase II reaction B LR Clonase reaction
TE buffer ad 10 µl TE buffer ad 10 µl
pDONR221 150 ng pDONR221 200 ng
attB-PCR product 150 ng pDEST-vector 300 ng
BP Clonase II 2 µl BP Clonase II 2 µl
The second step of the Gateway cloning aimed at a transfer of the vector. The coding sequence of
the target gene was transferred from the pDONR221 into a pDEST vector by LR-recombination.
Therefore the plasmid DNA of a positive clone of the first reaction was isolated and mixed with
the LR Clonase composition (Tab. 3.14 B). In general two pDEST vectors were used for the
experiments displayed here, pDEST53 with a N-terminal GFP and pCEV3.1 containing three con-
secutive N-terminal flag-tags. The reaction was placed on ice for 30 minutes and then transformed
in TOP10 Escherichia coli cells again.
3.2.3 Isolation of plasmids
Verified clones were transferred into a 15 ml falcon filled with 10 ml LB-Medium supplemented
with 10 µl ampicillin (100 mg/ml) or kanamycin (50 mg/ml) according to their respective resis-
tance cassette. After incubating this pre-culture for 8 hours at 37°C/220 rpm it was dispensed into
the main culture (100 ml, antibiotics as mentioned above) and cultured overnight on an orbital
shaker. The next day the bacterial suspension was sedimented by centrifugation and processed
with the PureLink kit (Invitrogen/Life Technologies) according to manufacturer’s protocol. Prior
to first preparation 340 µl of bacterial suspension were mixed with 50 µl glycerol and stored at
-80°C as glycerol stock.
3.2.4 Purification from gel
To isolate dsDNA after purification in gel the QIAQuick Gel Extraction Kit (Qiagen, Hilden,
Germany) was applied. The target band was excised from the gel and dissolved in buffer. The
spin-column approach provided a quick binding to a silica membrane in presence of high salt
content. After washing steps the DNA was eluted in H2O. The purified DNA was further used in
cloning experiments or Sanger sequencing.
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3.2.5 RNA isolation and cDNA synthesis
RNA was isolated from tissue, organ sections or cell culture by the RNeasy Kit (Qiagen). In brief:
Frozen organs and tissues were disrupted by mortar and pestle prior to the application. Ground
tissue/cells were lysed in a guanidine-thiocyanate-containing buffer supplemented with 1 % β-
mercaptoethanol. After passing through a shredder column the eluate was mixed with ethanol to
enable binding to a silica-based, column bound membrane. Several washing steps and two suc-
cessive DNase digestion steps were performed prior to eluting the pure RNA in water. After qual-
ity check and concentration measurement by NanoDrop the RNA was transcribed via RevertAid
Premium Reverse Transcriptase (Thermo Fisher Scientific, Rockford, USA). Transcription perfor-
mance was monitored by GAPDH PCR. Results shown in Fig. 4.2 were gained from purchased
cDNA (Clontech, Saint-Germain-en-Laye, France).
3.2.6 Analysis of proteins
Protein lysate
Depending on the cell type (suspension/adherent) the cells were either scraped with a rubber
scraper or sedimented by centrifugation. The cells were washed in PBS to remove any proteins
from the serum containing media and lysed in 1x DLB buffer, supplemented with 2 % protease
inhibitor cocktail and 1 % phosphatase inhibitor. After heating up the lysate for 5 minutes to
95°C, they were sonificated and finally centrifuged (15 minutes, 16000 xg, 4°C) to sediment cell
debris. The supernatant was transferred to a new tube and protein concentration measured via
Lowry assay according to manual (Bio-Rad, Munich, Germany). Protein quantification in this
assay was based on the work of Lowry et al. [178] and composed of a two-step reaction. A Biuret
reaction, where copper ions react with peptide bonds in an alkaline milieu under formation of a
blue complex was followed by the reduction of Cu(II) to Cu(I) which itself reduced the yellow
Folin-Ciocalteu reagent to molybdenum blue. This staining could be measured photometrically
at λ=650 nm. A standard curve based on known BSA concentrations was used to quantify the
measurements. Proteins were adjusted to a concentration of 1 µg/µl by adding PBS and 5x sample
buffer.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
Separating proteins according to their molecular weight was achieved by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGEs). This technique was based upon the findings of
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Laemmli et al. [179]. A SDS-PAGE consisted of two directly consecutive gels. The stacking gel
(3 % w/v polyacrylamide) took up the samples and focused them in the applied electric current.
The separation gel (7.5 to 15 % w/v polyacrylamide) could be passed faster by proteins with a
lower molecular weight. Depending on the system used a full separation of proteins between 15
and 150 kDa was achieved after 120 minutes (300 W, 300 V, 25 mA). Some samples were sepa-
rated on ice cooled pre-cast TGX gels (Bio-Rad) using following parameters: 500 W, 200 V, and
2500 mA for 45 minutes. If not otherwise specified 7.5 % SDS gels were poured, and run in TBS
buffer.
Western blot
To identify the proteins via antibody treatment the proteins had to be transferred from the SDS-gel
to a polyvinylidene fluoride (PVDF) membrane. A PVDF membrane was trimmed and activated
for 5 seconds in methanol. After washing in distilled water it was incubated in anode-buffer 1.
Three Whatman filter (Biometra, Göttingen, Germany) were cut in shape and soaked in anode-
buffer 1, 2 or cathode-buffer respectively. The Western blot stack was assembled in following
order (cathode-anode): cathode filter, SDS gel, PVDF membrane, anode filter 1, anode filter 2.
Blotting was performed in a Trans Blot Turbo (Bio-Rad) with 300 V, 300 W, and 0.8 mA/cm2
membrane for 90 minutes. After blotting the membrane was blocked in a 5 % skimmed non-fat
milk powder (Bio-Rad) solution. Blocking was followed by incubating the blot in primary anti-
body, washing in TTBS, incubation for 40 minutes with horseradish peroxidase (HRP)-coupled
secondary antibody, washing with TTBS, and finally incubating in ECL plus (GE Healthcare,
Freiburg, Germany) solution and developing on x-ray sensitive film.
Mass spectrometry
To investigate the protein composition of lysates and to confirm bands in SDS gels a MS/MS
run was performed on a LTQ Orbitrap Velos with ETD Support & UltiMate 3000 nano-HPLC
system (Dionex, Germering, Germany). After picking samples from a Coomassie stained SDS
gel the samples were separated and analyzed by reverse-phase liquid chromatography. Therefore
the samples were loaded on a PrepMap C18 trap column (Dionex), desalted and washed. After
eluting proteins to the analytic column Acclaim PepMap100 C18 (Dionex) two eluates (formic
acid and formic acid/acetonitrile) were applied in a linear gradient pattern. The eluted peptides
were analyzed on a LTQ Orbitrap Velos mass spectrometer (Thermo Scientific) equipped with a
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nano-electrospray ion source. The analysis was performed by D. Linke at the Institute of Experi-
mental Medicine (Kiel, Germany) under supervision of Prof. Dr. A. Tholey.
Co-Immunoprecipitation
To elucidate potential protein-protein interactions several Co-Immunoprecipitations were carried
out. This method relied on primary antibodies bound to agarose beads. Adding those beads to a cell
lysate would result in the binding of the antibody target protein. After sedimentation of the beads,
the antibody bound proteins could be purified and stripped off the beads afterwards. The proteins
precipitated could be either pure or still binding their interaction partner. This was verified by
SDS-PAGE and Western blot, being incubated with an antibody targeting the interaction partner.
To enhance specificity and purity several pre-clearing steps and washing steps had to be performed.
3.2.7 Coverslip staining
Cells were seeded into 6 well plates on sterile coverslips, transfected after 24 hours and washed af-
ter 48 hours with pre-warmed medium. In the following, cells were incubated with live cell stains,
such as Mitotracker (Life Technologies). Fixation was achieved by adding 4 % paraformalde-
hyde in PBS for 30 minutes, followed by three PBS washing steps. The cells were blocked and
permeabilized for 1 hour in PBS supplemented with 0.75 % bovine serum albumine and 0.1 %
Triton-X 100 (Carl Roth). Primary antibodies were diluted to their respective concentrations and
applied according to Tab. 3.7. The incubation was followed by washing steps and the incubation
with secondary antibodies for 45 minutes. The incubation was finalized by three washing steps
and a nuclear staining with DAPI if applicable. Coverslips were lifted with forceps and inversely
mounted onto a glass slide with Dako Fluorescent mounting medium (Dako, Glostrup, Denmark).
Staining and fluorescence were analyzed via Confocal laser scanning microscopy or wide field-
fluorescence microscopy. Samples were stored at 4°C in the dark afterwards.
Tab. 3.15: Microscopes. Three different microscopes were used. A confocal laser scanner microscope, a wide field-
fluoreschence microscope and an inverse light microscope.
type model manufacturer
CLSM TCS SP5 Leica
Fluorescence AxioImager.Z1 Zeiss
Inverse light h500 Hund
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3.3 Methods of cell biology
3.3.1 Cell culture
All human immortalized cell lines were provided by the "Deutsche Sammlung für Mikroorganis-
men und Zellkulturen GmbH" (DSMZ, Braunschweig, Germany).
Maintenance of cells
Work on cell lines, both maintaining and experimental, were conducted under a laminar flow bench
(HeraSafe, Heraeus Instruments GmbH, Hanau, Germany) under strict observation of germ-free
working. All materials, buffer, media, and chemicals were either filtered, autoclaved or thoroughly
wiped with 70 % ethanol (or respective commercial available disinfectant) prior to work. For culti-
vation, cells in media were exposed to 37°C, 5 % CO2. Cells were visually inspected twice a week
via an inverse microscope and split at 80 % confluence. For passaging, the cells were washed with
pre-warmed PBS (Gibco/Life Technologies) and trypsinized for 5 minutes with 1x Trypsin/EDTA
(Life Technologies). Exceptions were made for either RAW 264.7 cells, which were scraped or
confluent cells which were solely centrifuged. The reaction was stopped by adding serum con-
taining media and transferring the suspension to a 50 ml reaction tube. Cells were sedimented by
centrifugation at 600 xg for 5 minutes (Heraeus). The cells were resuspended in medium, counted,
and diluted 1:4 to 1:6 in a 25 ml cell culture flask (Falcon, Heidelberg, Germany). Cells were
passaged maximal 25 times. Cell counts were carried out using a Cellometer Auto T4 (Nexcelom
Bioscience, Lawrence, USA).
Isolation of Peripheral Blood Mononuclear Cells (PBMCs)
Peripheral blood mononuclear cells were isolated from human blood samples of voluntary donors.
The samples were applied on a Ficoll 400 kDa, poly sucrose 400 d:1.077 g/ml gradient (Biochrom
AG, Berlin, Germany). After centrifugation the interphase, containing lymphocytes together with
monocytes and platelets (buffy coat) was extracted and transferred to a new tube. Cells were
washed with PBS, sedimented and cultivated in RPMI+/+.
Cells in experiments
According to the experimental requirements cells were seeded into 10 ml dishes to 96 well plates
according to Tab. 3.16. For coverslip staining cells were seeded in a 6 well format onto a flame dis-




Tab. 3.16: Cell dilution and media volume. According to experimental needs, cells were seeded into following dishes.
format 10 ml 6 well 12 well 24 well 96 well
volume medium [µl] 10000 2000 1000 500 100
cell count
transfection 8x105 4x105 2x105 1x105 2x104
stimulation 1.2x106 6x105 3x105 1.5x105 2.5x104
3.3.2 Transfection
Plasmid transfection
Plasmids were transfected according to the FuGene 6 protocol (Roche, Basel, Switzerland). In
brief: The FuGene transfection reagent was mixed with medium and pipetted upon the plasmid.
The mixture was incubated for 30 minutes at room temperature and carefully dispensed upon the
cells in their respective media afterwards. Follow up incubation was carried out at 37°C and 5 %
CO2 for 48 hours if not stated otherwise.
RNA interference and siRNA transfection
RNA interference (RNAi) is a process of post-transcriptional gene silencing were the transfection
of small interfering RNAs (siRNA) into cells causes the destruction of messenger RNA (mRNA).
The RNAi pathway itself occurs naturally in most eukaryotic cells, detecting dsRNA as a marker
for i.e. dsRNA-virus intrusion. As the inhibition of gene expression could be achieved by inject-
ing dsRNA directly into the larvae/adults of Drosophila melanogaster or Caenorhabditis elegans,
those organisms became pioneering organisms in gene inhibition studies [180]. The direct injec-
tion of dsRNA into human cell culture was a not applicable method due to a strong interferon
response [181, 182]. Reducing the size of the siRNA to 21 to 22 nucleotides and designing special
complementary sequences resulted in a specific knockdown of genes [183]. If not other specified
siRNAs were purchased from the silencer select product line (Life Technologies). Upon arrival
the lyophilized siRNAs were solved in RNase free water to a concentration of 10 µM. The siRNA
transfection was carried out according to the siPORT Amine transfection protocol (Life Technolo-
gies). In brief: The siPROT Amine transfection reagent was diluted in OPTI-MEM medium, as
were the siRNAs. After incubating both solutions for 10 minutes at room temperature they were
combined and carefully dispensed onto the cells in their respective media, giving a final concen-
tration of 5 nM siRNA. The plates were gently tilt to reach optimal mixing and incubated at 37°C




Stimulation experiments were carried out according to Tab. 3.17.
Tab. 3.17: Stimulants. The LPS from the Forschungszentrum Borstel (Leibniz Institute) was provided by the group of
Prof. Dr. U. Zähringer.
Stimulant concentration supplier remarks
LPS
Sigma-Aldrich 100 ng/ml Sigma-Aldrich L4524 E. coli 055:B5
Invivogen 100 ng/ml Invivogen Ultra Pue LPS E. coli K12
Borstel 100 ng/ml Research Center Borstel E. coli Nissle 1917 DSMO
various
2C11 1 µg/ml Inst. of Immunology 50 µl coating of wells
PHA 1 µg/ml Sigma-Aldrich
PMA 10 ng/ml Sigma-Aldrich
Ionomycin 200 ng/ml Sigma-Aldrich
TNFα 50 ng/ml Invitrogen single stimulation
TNFα 20 ng/ml Invitrogen co-stimulation
Tunicamycin 10 µg/ml Calbiochem
The stimulation experiments were designed in a way to be harvested at a common end point. This
ensures, that the cells were all exposed to the same general cell culture conditions for an equal
period of time.
3.3.4 Cell fractionation
Cell fractionation was achieved by a differential centrifugation protocol modified after Kwon et
al. [184]. All buffers were supplemented with phosphatase and protease inhibitors. The cells were
harvested and lysed (cell fractionation buffer 1, Tab. 3.9) on ice. The incubation was followed by
shearing the cells via a 26G needle on a syringe. The lysate was centrifuged (10 minutes, 1000
xg, 4°C). The nuclei containing sediment was resuspended in cell fractionation buffer 2 and kept
on ice for 30 minutes while the supernatant was further separated by centrifugation (45 minutes,
16000 xg, 4°C). The second pellet contained the cell membrane and was resuspended in PBS,
while the supernatant provided the cytosolic fraction. All fractions were snap frozen in N2(l).
3.3.5 Isolation of mitochondria
Mitochondria were isolated via the Abcam Mitochondria Isolation Kit (Abcam, Cambridge, UK)
according to manufacturer’s protocol. In brief: Cells were harvested, buffered, and lysed by 25
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strokes of a Dounce homogenizer. The lysates were differentially centrifuged to receive a purified
mitochondrial fraction.
3.3.6 Dual luciferase assay
The dual luciferase assay enables a quantification of NFκB activation. Therefore the dual lu-
ciferase system relied on two plasmids. Plasmid A (pNFκB-Luc, Clontech, Heidelberg, Germany)
contained a luciferase originating from the firefly Photinus pyralis, plasmid B (pRL-TK, Promega,
Madison, USA) a luciferase from the sea pansy Renilla reniformis. While the luciferase from plas-
mid A oxidized luciferin to oxiluciferin under emission of light with λ=550 to 570 nm, luciferase
from plasmid B catalysed the oxidation of coelenterazine to coelenteramide under the emission of
light with λ=480 nm. The luciferase of pNFκB-Luc was under control of three NFκB-consensus-
enhancers, thus expressing the luciferase and therefore oxidizing luciferin directly depending to
the intracellular NFκB level. The luciferase of the pRL-TK was under the control of a thymidine-
kinase promoter of a Herpes simplex virus. It was constitutively expressed in all transfected cells,
thus giving a reliable value for cell viability and cell count. The firefly luciferase values were nor-
malized to the Renilla values to achieve comparable results throughout the experiments. As both
luciferases relied on different substrates and pH level this system was suitable for an automated
read out by a GeniosPRO microplate reader (Tecan, Männedorf, Switzerland). Measurements were
done on HEK-293 cells, seeded in 96 well plates and transfected 24 hours after seeding. Stimu-
lation, if applicable, occurred 24 hours after transfection. After incubation the supernatant was
discarded and the cells lysed in 1x passive lysis buffer (Promega). Lysate was transfered into a
white 96 well plate. The luciferase substrates were mixed and applied according to manufacturer’s
protocol (Promega). Readout was conducted via a GeniosPRO microplate reader. The quotient of
both luciferase activities was calculated and depicted as relative luciferase unit (RLU).
3.3.7 Enzyme-linked immunosorbent assay
Supernatant of stimulated cells were harvested to carry out enzyme-linked immunosorbent assay
(ELISA). This antibody based technique facilitated the quantification of i.e. interleukins in the su-
pernatant. In the present experiments CytoSet Kits were used according to manufacturer’s protocol
(Life Technologies). In brief: Nunc 8 well stripes (Thermo Scientific) were coated with a primary
antibody overnight. After a blocking step the cell supernatant was applied for 1 hour, enabling the
antibodies to bind their targets. After several washing steps a streptavidin HRP-coupled secondary
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antibody was applied, followed by a washing step and the administration of a TMB-substrate solu-
tion. After 30 minutes the reaction was stopped by adding HCl. The absorbency at λ=490 nm was
read out photometrically. Quantification was enabled by a standard series of recombinant target
proteins processed in parallel.
3.3.8 MTS assay
The MTS assay was a non-radioactive, colorimetric cell-proliferation assay. The chemical 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium reacts
in the presence of the electron coupling reagent phenazine methosulfate. In vivid cells endogenous
dehydrogenases were expressed leading to the conversion of MTS to the soluble formazan. The
OD could be measured at λ=490 nm.
3.4 Generation of Nlrc3-/- mice
To study the effect of Nlrc3 in an in vivo system a knockout mouse model was generated. Due to a
Nlrc3-gene size of approximately 38 kb, the deletion of the whole gene was not a suitable option.
It has been agreed to target the exons 2 and 3 of Nlrc3 instead, therefore deleting approximately
2.5 kb (1990 bp of the coding sequence). This deletion results in the loss of 661 aa, containing
the potential CARD- and the NACHT-domain. The generation of a constitutive Nlrc3 knockout
was achieved by targeting and inserting a distal loxP-site and a FRT-neomycin-FRT-loxP cassette
into intron 1 and 3. The overall deletion was achieved by two consecutive in vivo excisions. A
summary of the cloning strategy and recombination events is given in Fig. 3.2.
A more detailed explanation of the homologous recombination and cloning strategy per-
formed by genOway (Lyon, France) is given in the chapter Supplements (chapter 6). Hav-
ing reached sexual maturity, the highly chimeric males were crossed with Flp deleter
C57BL/6N females to enable the in vivo excision of the neomycin selection cassette.
The heterozygous knockout F1 mice were validated by Southern blot. Therefore the ge-
nomic DNA was digested by PspOMI, blotted and hybridized with a 418 bp probe
generated by PCR (5’-CTGAAGCAGTAGAACCACAGTAAGACTGAGAGG-3’ and 5’-
GAAGGTAATGCTCAAGTCAGGGCAGGC-3’). The WT resulted in a 6283 bp, the floxed in
a 10512 bp fragment. The gained offspring was bread as constitutive knockout mice. Mice were
backcrossed for nine generations onto a C57BL/6N background. The genotype was frequently
checked during the breeding process by PCR. An example of the genotyping PCRs, enabling the
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Fig. 3.2: Murine Nlrc3 gene cloning. A summary of the cloning strategy and recombination events is given. The exons
2 and 3 were flanked by a loxP-site and a FRT-neomycin-FRT-loxP cassette. The Neo-cassette was excised in vivo to
generate a floxed Nlrc3 locus. Mating the floxed mice with Cre-mice resulted in the excision of the floxed gene region.
Diagram is not depicted to scale. Boxes represent exons, solid lines intronic sequences.
distinction between WT and KO is given in Fig. 3.1, the oligomers are listed in Tab. 3.5. The mice
were housed in a separated facility fulfilling SPF-standards according to Federation of European
laboratory animal science associations (FELASA).
3.4.1 Handling of mice
Mice were kept in individually ventilated cages, up to maximal five litter mates per cage. A strict
12 hours/12 hours light cycle with 60 - 400 Lux was established and a temperature between 20 -
24°C maintained. Air humidity was kept at 55 % at a ventilation rate of 8 - 20 fold. IVC cages
were bought from Bioscape GmbH (Castrop-Rauxel, Germany) or Tecniplast (Hohenpeißenberg,
Germany). Tap water and standard caloric food were given ad libitum. Mice were bred in separated
cages. After pregnancy of 21 days the offspring was separated from the mother by the age of
4 weeks and genotyped. All experiments were performed on animals aged between eight and
sixteen weeks as they were considered adult and homeostatic. Animals were sacrificed by cervical
dislocation.
All animal experiments were in concordance with federal law and monitored by an independent




3.4.2 Bone marrow derived macrophages
Murine bone marrow derived macrophages (BMDMs) are leukocytes derived from murine femur
and tibiae bone marrow. These primary cells were a tremendous, unbiased model to study murine
immune system related processes.
The mice were sacrificed by cervical dislocation. After removing femur and tibiae, they were
stripped of any adherent material. The joints were cut off and the bone marrow was flushed out
with BMDM medium (Fig. 3.4). After suspending the cells they were filtered through a 70 µm
cell strainer, plated in 150 mm dishes, and cultivated at 37°C/5 % CO2. Macrophage medium
had to be supplemented with macrophage colony-stimulating factor. This lineage-specific growth
factor enabled the proliferation and differentiation of committed myeloid progenitors into cells
of the macrophage/monocyte lineage [185]. BMDMs were cultured for three days, than medium
was replaced or replenished according to cell development. After about seven days (depending
on visual inspection) the adherent cells were harvested, count, and seeded into appropriate cell
culture dish according to Tab. 3.18.
Tab. 3.18: Cell density for BMDM experiments. Depending on experimental needs, the BMDMs were seeded ac-
cording to this table.
format 10 ml 6 well 12 well 24 well 96 well
volume medium [µl] 10000 2000 1000 500 100
cell count 6x106 1x106 0.5x106 2.5x105 5x104
3.4.3 Mixed splenocytes
Murine mixed splenocytes were employed as a T cell model. Spleen was removed from sacrificed
mice and pressed through a 70 µm cell strainer. Cells were suspended in RPMI+/+, supplemented
with 1 % of the antifungal agent amphotericin and 1 % glutamine. Cells were counted and plated
to culture dishes according the experimental requirements.
3.4.4 Acute dextran sodium sulfate induced colitis
Procedure
Acute dextran sodium sulfate (DSS) colitis was slightly modified after Wirtz et al. [186]. Male
C57BL/6 Nlrc3-/- and C57BL/6 Nlrc3+/+ mice (aged 11 - 13 weeks) were housed in SPF-conditions
according to FELASA standards. They were granted unlimited access to food pellets and drinking
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water. Animals were kept in groups separated by their genotype but masked to the experimenter (8
WT, 9 KO, 3 KO-Ctrl.). Mice were given autoclaved tap water, supplemented with 4 % (w/v) DSS
ad libitum for 5 days. The solution was changed once during this time to prevent bacterial growth
in the water, water consumption was recorded. After 5 days with DSS administration the drinking
water was replaced by pure autoclaved water. Mice were sacrificed upon day 8 or when reaching
stop criteria. During the whole experiment three separated mice Nlrc3-/- were fed consequently
with autoclaved tap water as control.
Stop criteria
The three major features: obvious pain, weight loss >25 %, and death were assigned as stop criteria
for each mouse. Upon reaching one criteria the mouse was taken from the experiment, sacrificed
by cervical dislocation (if applicable), and further processed.
Daily scoring
Body weight measuring, occult blood in stool analysis, and stool consistence were checked and
scored on a daily basis according to the parameters given in Tab. 3.19.
Tab. 3.19: Disease Activity Index (DAI). Rectal bleeding was scored via Haemoccult test from Beckman Coulter
(Krefeld, Germany).
DAI weight loss [%] stool consistency rectal bleeding
0 0 formed Hemoccult neg.
1 1 - 5
2 6 - 10 unformed Hemoccult pos.
3 11 - 20
4 >20 liquid visible
Final analysis
The mice were anesthetized with ketamine (100 mg/kg bodyweight) and xylazine (16 mg/kg body-
weight) to enable endoscopic examination. The parameters for scoring according the modified
murine endoscopic index of colitis severity (MEICS) score [187] are given in Tab. 3.20. After en-
doscopy the still anesthetized mice were coronary punctured. The blood was kept clotting for 30
minutes and centrifuged for 5 min at 10000 xg to gain serum. The serum was snap frozen in N2(l).




• The spleen was weighted and its length measured. Afterwards one half was snap frozen, the
other half was preserved in 10 % formaldehyde.
• Liver and mesenchymal lymph nodes were snap frozen.
• Colon was flushed with PBS, its length measured, and photographed. Subsequently the
colon was cut longitudinally. A small piece was cut from the distal part and snap frozen. The
rest was rolled up from distal to proximal, embedded into a Histo-cassette and stored under
10 % formaldehyde until further processing.
• The ileum was sampled and cut accordingly.
All snap frozen organs were ground and further processed as mentioned in subsection 3.2.5.
Tab. 3.20: Modified murine endoscopic index of colitis severity score. Proxies of the MEICS score modified after
Becker et al. [187].
Score Thickening Changes of vascular Fibrin visible Granularity of Stool
of colon pattern mucosal surface consistency
0 transparent normal none none solid
1 moderate moderate moderate moderate still shaped
2 marked marked marked marked unshaped
3 nontransparent bleeding extreme extreme spread
3.4.5 Histology
The organs and histological rolls were fixed in 10 % neutral buffered formalin, dehydrated, and
embedded in paraffin wax. Blocks were cut to 3.5 µm sections on a Leica RM 2255 microtome
(Leica Microsystems, Wetzlar, Germany) and collected on microscope slides.
Hematoxylin and eosin staining (HE staining)
The histological sections were deparaffined in a decreasing alcoholic dilution series, stained in
hemalum, and dyed in tap water. After staining with Eosin G the sections were dried in an increas-
ing alcoholic series and preserved with Roti Histokit. Hemalum, a complex formed of aluminium
ions and oxidized haematoxylin, functions as a DNA independent nuclear stain, which stains the
rER, too. The synthetic acidic eosin Y eosinophilic stains structures, such as proteins of the cyto-




The coverslips were prepared as mentioned above. The deparaffining was achieved by substituting
paraffin with the xylol substitute Roti-Histol (Carl Roth), followed by incubation in a decreasing
alcoholic dilution series, and washing in PBS. After saturating endogenous peroxidases by a 3 %
H2O2 treatment the sections were blocked with the respective VectorStain Elite serum (Vector-
Lab, Burlingame, USA). Primary antibody was applied in a humidified chamber to the sections
and incubated overnight. Following several washing steps in PBS the sections were incubated
with the corresponding biotinylated secondary antibody VectorStain (VectorLab) for 45 minutes.
Successively the sections were washed, treated with the VECTASTAIN Elite ABC reagent, and
finally incubated with a peroxidase substrate solution until the final brownish stain became visible.
The reaction was stopped by PBS and aqua dest. washing steps. Counter staining was achieved
by bathing the sections in haematoxylin (Carl Roth), blueing under rinsing tap water, drying in an
increasing alcohol dilution series and embedding in mounting medium.
Additionally, the IMMT and NLRC3 antibody were tested for histological usage and found to be
not suitable for this purpose.
3.4.6 Blood analysis
After sacrificing the mice, blood samples were taken from Nlrc3-/- mice out of the heart or the main
abdominal vein. Analysis was performed by ACCU-CHEK (Roche, Mannheim) for blood glucose
[188] and by HPLC of EDTA-blood to measure HbA1c levels. Coronal punction of anesthetized
mice was not suitable, as it has been shown, that different agents heavily impact blood glucose
level [189].
3.5 Statistical analysis
All quantitative numeric data were tested for statistical outlier, using QuickCalcs Outlier Calcula-
tor (GraphPad Software Inc., La Jolla, USA). A value of z=0.05 was taken as confidence value. The
examined data were corrected for outlier and plotted with MEAN and SEM in GraphPad Prism
(GraphPad Software Inc.). In few cases not all data points could be depicted in the shown range
of graph, which did not affect the statistics. Statistical analysis was conducted by a two-sided, two
parametric Student’s t-test, where applicable. Significance levels were marked as (*) for p≤0.05,




4.1 NLRC3 is differentially expressed in various tissues
To assess questions regarding the function or typical characteristics of NLRC3 it is important to
know which tissues/cells express NLRC3 either on mRNA or protein level.
4.1.1 Nlrc3 is expressed in cDNA of immune related tissues
After sacrificing a Nlrc3(+/+) male and female mouse, organs were obtained, RNA was isolated,
translated into cDNA, and analyzed by endpoint PCR. A Nlrc3-specific fragment was amplified.
The result is shown in Fig. 4.1 in comparison to mGAPDH as housekeeper.
Fig. 4.1: Endpoint PCR on murine cDNA. Mice were sacrificed, organs removed, and lysed. RNA was isolated and
transcribed into cDNA. Two samples (skel. muscle and heart) were taken from a Clontech cDNA kit. An endpoint PCR
was carried out, using m10 and mGAPDH oligomers. Human plasmid cDNA was used as control resulting in a slightly
higher amplicon band and a lack of a mGAPDH signal. Blot shown is representative. The results are shown in inverted
gray scales.
The strongest signals were gained for spleen, bone marrow, lymph node, testis, and thymus. The
mGAPDH housekeeper showed equal amounts of cDNA in the samples. As a Nlrc3 containing
plasmid was used as positive control no mGAPDH bands were expected here. A representative
band was excised, purified and verified by Sanger sequencing.
4.1.2 High transcript level of NLRC3 and Nlrc3 are found in immune related
tissues, but not in the intestinal tract
To further quantify the expression of NLRC3 and Nlrc3 two qPCRs were carried out. The results
are shown in Fig. 4.2. The highest expression of human NLRC3 was observed in spleen, lymph
node, thymus, leukocytes, and tonsil (increasing order). Murine tissues showed highest Nlrc3 ex-
pression in spleen, heart, adrenal gland, thymus, and lymph node (increasing order), indicating
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distinct similarities between the species.
Fig. 4.2: Expression analysis of human and murine NLRC3/Nlrc3. Commercial available cDNA samples were an-
alyzed via qPCR. The values were normalized against β-Actin as housekeeper. The x-axis shows the organs of which
the cDNA originates, the y-axis depicts the normalized expression. A Shows the results from the human samples and
B the results from the murine samples. All samples were analyzed in two technical replicates. Murine samples contain
male/female when applicable.
4.1.3 NLRC3/Nlrc3 in human and murine cell lines
Established cell lines were checked for their endogenous NLRC3 protein expression (Fig. 4.3).
Fig. 4.3: Endogenous expression of NLRC3 in cell lines. A Several cell lines were cultivated and harvested from a 10
ml dish. Cells were lysed with DLB buffer and proteins analyzed via Western blot. B NLRC3-GFP was overexpressed
in HEK-293 cells. The cell were either kept untreated (1st lane) or were transfected with siRNA. The results in the
2nd lane are based on control siRNA transfection, siRNA1-3 represent different NLRC3 specific siRNAs. The blots
were incubated with A 1:500 α-NLRC3, B 1:250 α-NLRC3, and 1:10000 α-β-Actin antibodies (A+B), detection was
performed with HRP linked species specific secondary antibody and ECL.
NLRC3 was expressed in all tested cell lines. Additionally to the human cell lines, two murine
cell lines (RAW 264.7 and ModeK) were tested, too, and found to be Nlrc3 positive. One of the
strongest expressions was observed in HEK-293 cells. As HEK-293 cells are well known to be
easily transfectable they were used for most of the following in vitro experiments. A strong signal
was observed in the colon carcinoma cell line CaCo-2 cells, but cDNA analysis failed to show
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elevated transcript levels either in end-point PCRs or in qRT-PCR analysis (Fig. 4.1, 4.2). The
siRNA experiment (Fig. 4.3 B) proofed the specificity of the primary antibody.
4.1.4 Cell fractions demonstrate the cytosolic localization of NLRC3
After demonstrating a strong signal of NLRC3 in HEK-293 cells and having elucidated a pre-
ferred expression in cells of the immune system cell fractionations were carried out. Peripheral
blood mononuclear cells isolated from human buffy coats, contained lymphocytes, monocytes,
and platelets and therefore a subset of the most important cells of the adaptive and innate immune
system. The cell fractions were analyzed via Western blot (Fig. 4.4).
Fig. 4.4: Cell fraction of human PBMCs and HEK-293 cells. Human PBMCs were isolated and fractioned by dif-
ferential centrifugation. The same protocol was applied to HEK-293 cells from cell culture. The lysates were analyzed
by Western blot. The blot was incubated with α-NLRC3 (1:500), α-β-Tubulin (1:1000) as compartment control, and
α-β-Actin (1:10000) as loading control.
NLRC3 was solely expressed in the cytosol of the PBMCs and HEK-293 cells tested. The fraction
contained a strong tubulin signal, being a specific marker for the cytosol. The NLRC3-signal was
even stronger in HEK-293 cells, although the separation was not fully successful according to
the tubulin signal. The positive control, being generated from HEK cells overexpressing NLRC3,
confirmed the specificity of the NLRC3 signal.
4.2 Analysis of functional interaction and colocalization between NLRC3
and Mitofilin
An early Yeast-2-hybrid screen has been performed by Billmann-Born et al. [data not shown],




4.2.1 Co-immunoprecipitation of NLRC3 and IMMT
Co-Immunoprecipitations were used to test for direct protein-protein interactions (Fig. 4.5).
Fig. 4.5: Co-Immunoprecipitation of NLRC3 and IMMT. HEK-293 cells were either stimulated with TNFα or kept
unstimulated. They were lysed and incubated with either, α-IMMT, α-IgG mouse (as IMMT Ctrl.), α-NLRC3 or α-
IgG rabbit (as NLRC3 Ctrl.) bound to agarose beads. Precipitates were purified and blotted. Blots were incubated with
α-IMMT and α-NLRC3 antibody.
While both, NLRC3 and IMMT, were detectable in the cell lysates of HEK-293 cells, no NLRC3
was detectable in the samples pulled with α-IMMT antibodies. The same holds true for the sam-
ples pulled with α-NLRC3 antibody. A positive signal was gained in the IMMT pulled samples for
IMMT. The negative controls, consisting of IgGs equal to the species in which the α-NLRC3 (rab-
bit) or respectively the α-IMMT (mouse) antibody were generated, showed no band. A stimulating
effect of TNFα could not be shown.
4.2.2 Cell staining reveals spatial position of NLRC3
Coverslip stainings were performed to assess the localization and potential interaction of NLRC3
with other proteins or cell structures. All stainings were designed with an IgG control as well
as a mock-transfected control. First cells were tested for endogenous NLRC3 and overexpressed
NLRC3-flag. Endogenous NLRC3 signals were weak, but overexpressed NLRC3-flag could be
successfully detected by either α-NLRC3 or α-flag-antibodies. Both signals appeared close to the
Mitotracker signal as seen in the merged pictures. Accordingly, the NLRC3 antibody from Abcam
was applied in combination with the mitochondrial dye Mitotracker, and α-IMMT as shown in
Fig. 4.7.
Each setup consisting of a NLRC3-flag and a mock transfected sample was stained with Mito-
tracker, DAPI, and a specific, antibody based AlexaFluor dye. While the stains were kept constant
between the setups A-C in Fig. 4.6, the antibody based staining (2nd column) altered. Unspecific
binding of the secondary antibody could be excluded, as the IgG control was negative (Fig. 4.7 A
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Fig. 4.6: Coverslip staining of HEK-293 cells comparing α-NLRC3 and α-flag-antibody. HEK-293 cells were
seeded onto coverslips and transfected either with a mock vector or a NLRC3-flag vector. The cells were cultivated for
two days and stained with Mitotracker (red signal). After PFA fixation and permeablilization the cells were incubated
with primary antibodies as followed: A α-rb-IgG, B α-flag, C α-NLRC3. The primary antibodies were detected by
the respective AlexaFluor-488 coupled secondary antibody, giving a green signal. Finally, the cells were stained with
DAPI, resulting in a blue signal for nucleic acid.
and 4.6 A). A rabbit α-IgG was used as primary antibody control. While DAPI and Mitotracker
produced distinct signals, no green fluorescence was observed. The α-flag antibody (Fig. 4.6 B)
resulted in a strong signal in cells overexpressing NLRC3-flag. When merging all three channels
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Fig. 4.7: Coverslip staining of HEK-293 cells with α-Mitofilin-antibody. HEK-293 cells were seeded onto cover-
slips and transfected either with a mock or a NLRC3-flag vector. The cells were cultivated for two days and stained
with Mitotracker (red signal). After PFA fixation and permeablilization the cells were incubated with primary antibod-
ies as followed: A α-rb-IgGα, B α-Mitofilin, C α-NLRC3. The primary antibodies were detected by the respective
AlexaFluor-488 coupled secondary antibody, giving a green signal. Finally, the cells were stained with DAPI, resulting
in a blue signal for nucleic acid.
distinct cell features and yellow areas of overlapping signals became visible. The positive con-
trol, using an α-NLRC3 antibody, binding both, endogenous and exogenous, NLRC3 is shown in
Fig. 4.6 C. Merging the channels, showed very few antibody specific green signals for endoge-
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nous NLRC3 (in the mock control) and a specific overlap in the transfected cells. As expected,
the successive incubation with Mitotracker and α-Mitofilin (Fig. 4.7 B) showed colocalization as
demonstrated by the wide overlap in the merged picture. This effect appeared to be even increased
in the NLRC3-transfected cells. Applying a successive staining with Mitotracker and α-NLRC3
in NLRC3-flag transfected HEK-293 cells resulted in a specific overlap as indicated in the lower
merged picture in Fig. 4.7 C.
In a third experiment HeLa cells were transfected with NLRC3-flag matching the previous exper-
imental setup (Fig. 4.8).
Fig. 4.8: Coverslip staining of HeLa cells. HeLa cells were seeded onto coverslips and transfected with a NLRC3-
flag vector. The cells were cultivated for two days and stained with Mitotracker (red signal). After PFA fixation and
permeabilization the cells were incubated with primary antibodies as indicated in the pictures. The primary antibodies
were detected by the respective AlexaFluor-488 coupled secondary antibody, giving a green signal. Finally, the cells
were stained with DAPI, resulting in a blue signal for nucleic acid.
These results indicate a close spatial proximity of NLRC3 and IMMT and are therefore in concor-
dance with the results shown previously (Fig. 4.6). Having shown the same effect independently
in two different cell systems strengthens the theory of NLRC3 being in close proximity to mito-
chondria.
Finally, a staining for CLSM analysis was conducted. HEK-293 cells overexpressing NLRC3-flag
were incubated with α-flag and Mitotracker (Fig. 4.9). As shown in Fig. 4.9 A are the signals
from α-Mitofilin and mitotracker matching perfectly, resulting in a yellow signal. The white spots
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Fig. 4.9: Staining for CLSM analysis. HEK-293 cells were seeded onto coverslips and transfected with a NLRC3-
flag vector. The cells were cultivated for two days and stained with Mitotracker (red signal). After PFA fixation and
permeabilization the cells were incubated with primary antibodies as indicated in the pictures. The primary antibodies
were detected by the respective AlexaFluor-488/-633 coupled secondary antibody, giving a green/purple signal. A The
merged signals of the secondary antibodies and the mitochondrial stain can be merged to an image, where white areas
indicate an overlap of all three channels. B The α-NLRC3 signal and the Mitofilin signal of cells were merged and
analyzed. The white areas indicate areas of perfect overlap. The last image shows a distribution of the signals. Dots
near to the color-axis represent non matching signals, while dots appearing yellow result from overlapping signals.
NLRC3 signals are shown in false color here.
in the merged picture indicate the overlap of all three signals, further hinting at a close spatial
proximity of NLRC3 and mitochondria. Due to the higher intensity of the stain a new picture
was taken for the overlap of Mitofilin and NLRC3 signals (Fig. 4.9 B). The potential correlating
signals are indicated in white. A correlation analysis of those signals, as shown in the fourth panel,
revealed that most of the signals are indeed overlapping. All signals appearing yellow in the dot
plot are considered to be perfect matches. All other dots (red/green), which are located nearer to
their respective axes represent non-matching single signals.
4.2.3 NLRC3 was detected in a mitochondrial lysates via MS/MS
Having detected NLRC3 in close spatial proximity of mitochondria (subsection 4.2), mitochon-
drial lysates and two protein samples from Co-IPs were analyzed via MS/MS. All samples were
based on HEK-293 cells, overexpressing NLRC3. While the α-IMMT pulled sample was pre-
stimulated with TNFα, the α-NLRC3 pulled sample was kept unstimulated. After Coomassie
staining, several bands were extracted (Fig. 4.10) and analyzed (Tab. 4.1).
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Fig. 4.10: Coomassie stained gel for MS/MS anal-
ysis. Lane 1: marker; lane 2: mitochondrial lysates
from HEK-293 cells; lane 3: Co-IPs from HEK-
293 cells overexpressing NLRC3, stimulated with 50
ng/ml TNFα and pulled with α-Mitofilin; lane 4:
Co-IPs from HEK-293 cells overexpressing NLRC3
pulled with α-NLRC3 were separated on a SDS-
PAGE and stained with coomassie. The arrows indi-
cate spots sampled for MS/MS analysis.
Tab. 4.1: Excerpt of proteins identified via MS/MS. The
sample numbers correlate with those indicated in Fig. 4.10.
The accession number refers to the UniProt database. The
full list of identified proteins is available on a compact disc
attached to this thesis.
ID size lane description accession
[kDa]
1 130 2 NLRC3 B5MDB6
mHsp 60 B7Z5E7
keratin P13655
2 250 2 PRP8 hom. Q6P2Q9
keratin P13645
3 260 2 ELYS Q8WYP5
keratin P13645
4 >260 2 DNA-PKcs P78527
keratin P13645
5 >250 3 keratin P13645
6 <250 3 keratin P13645
7 <250 4 keratin P13645
8 >250 4 keratin P13645
9 <130 2 uncertain spectra
10 <130 3 Mitofilin Q16891
keratin P13645
A positive NLRC3 signal was detected in the lysate at approx. 130 kDa, while no NLRC3 was
detectable in the α-NLRC3 pulled samples. The α-IMMT sample produced a positive MS hit for
IMMT. Further samples were found positive for keratin mainly, an ubiquitous bias of this analy-
sis. High molecular weight bands of the mitochondrial lysate did not reveal NLRC3 as potential
constituent of protein complexes. Hits as Q6P2Q9 in sample 2 indicate that this method is suitable
even for large proteins, but that the mitochondrial isolation may be biased by small sub-nuclear
structures like speckles. Staining and separation experiments did not indicate a nuclear localization
of NLRC3. The full list of hits is available in the electronic supplements (see chapter 6).
4.2.4 In silico prediction of probability of NLRC3 being imported into
mitochondria
To calculate the probability of the import of NLRC3 into mitochondria the protein sequence was
analyzed by two different algorithms. The MITOPROT algorithm has been published by Claros
et al. [190] and has been provided by the Institute of Human Genetics at the Helmholtz Center
Munich (Tab. 4.2 A). The Predotar algorithm was provided by the French National Institute for
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Agricultural research (Tab. 4.2 B) [191]. Both algorithms aimed at the identification of a puta-
tive N-terminal targeting sequence. The predictions are summarized in Tab. 4.2, while a graphic
overview of the isoforms mentioned is given in the supplements of this thesis (chapter 6).
Tab. 4.2: Probability of NLRC3/Nlrc3 to be imported into mitochondria. A The results are based on calculations by
MitoProt II - v1.101 and B Predotar v. 1.03. The human inner mitochondrial membrane protein Mitofilin was calculated
as positive control.
A B
protein isoform size [kDa] probability value of export
into mitochondria
human NLRC3 1 114.658 0.0445 0.01
2 119.415 0.1095 0.0
3 83.456 0.06 0.01
4 111.634 0.09 0.01
Mitofilin 1 83.678 0.9825 0.63
murine Nlrc3 1 115.993 0.0811 0.26
2 80.819 0.0041 0.0
3 41.669 0.8004 0.0
4 32.882 0.788 0.0
5 25.538 0.061 0.0
The positive control Mitofilin showed a high probability to be imported into mitochondria. The
calculated values for NLRC3 were lower, varying between the different isoforms. Depending on
the algorithm a quite high probability has been predicted for the murine Nlrc3 isoforms 3 and
4. They are both missing the NACHT domain, but still express several LRRs. This is true for
isoform 5 as well, although the algorithm computed a more than tenfold lower probability. This
demonstrates the sensitivity of the algorithm, which calculates a probability based on 47 different
parameters. A conserved signal recognition protein, comparable to those discovered by Blobel et
al. has yet not been described for mitochondria [192]. Instead, a variety of cleavable presequences
and noncleavable targeting and sorting signals were published, indicating a complex protein sort-
ing system [193].
4.2.5 NLRC3 influences the ERSE mediated unfolded protein response
Having strong support for an interaction of NLRC3 and mitochondria, especially with IMMT it
was interesting to follow up a potential functional trait. Cellular stress may result in misfolding
or unfolding of proteins. The unfolded protein response (UPR) has been described for the ER
[194, 195, 196]. The UPR controls the activation of i.e. molecular chaperones or enzymatic sets to
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refold or dispose the incorrect folded proteins. The endoplasmic reticulum stress element (ERSE)
which is inducible by ATF6, XBP1, and p50 is a central promoter in the upregulation of unfolded
protein response related proteins like the glucose regulated proteins (grp) [197]. A significant
activation of UPR should therefore be detectable by an increased ERSE promoter activity.
Fig. 4.11: Impact of NLRC3 on tunicamycin induced ERSE promoter activity. HEK-293 cells were either trans-
fected with 5 ng NLRC3-flag or a flag-vector. An ERSE-Luc and a pRLTK were also transfected. The total DNA amount
was kept constant by the use of an empty vector. A stimulation regime with 50 ng/ml TNFα, 10 µg/ml tunicamycin,
and cell culture medium as negative control was applied. Each bar summed up from 2 experiments, n=10 samples prior
to statistical correction. Significance levels were evaluated by Student’s t-test.
The data shown in in Fig. 4.11 are based on repeated experiments, which have been normalized
to the unstimulated controls. The ERSE promoter activity was not affected by TNFα, but highly
upregulated after tunicamycin stimulation. NLRC3 overexpressing cells exhibited a higher ERSE
promoter activity after tunicamycin stimulation. An increased activation of ERSE indicated the
activation of the downstream UPR cascade. The cell fate depends upon the further regulation of
this cascade [198].
4.3 NLRC3 and its impact on NFκB activation
As the NFκB pathway is well known to be interconnected with inflammatory processes, a potential
impact of NLRC3 was tested. One of the most convenient readouts at hand was a dual luciferase
assay, enabling the direct quantification of NFκB activation in relation to a housekeeper.
Following experimental procedures, described by Conti et al. [50], several luciferase experiments
were conducted. Utilizing the same amounts of plasmid as mentioned in the publication failed to
produce reliable data [data not shown]. Decreasing the total amount of plasmid to a maximum of
50 ng per sample resulted in the data shown in Fig. 4.12.
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Fig. 4.12: Dual luciferase assay in HEK-293 cells. HEK-293 cells were transfected with a NFκB-Luc and a pRLTK-
Luc construct. Additionally, different amounts of NLRC3-GFP (5, 17.5, and 35 ng) were transfected. The total amount
of plasmid was kept constant by the addition of an empty vector. Half of the cells were stimulated with TNFα for eight
hours, the other cells were kept unstimulated. The unstimulated negative controls were transfected with 5 and 35 ng
NLRC3-GFP respectively. The 17.5 ng transfected control is not depicted and did not show any elevated values. The
data shown are a summary of four independent results, with each n=10 samples per column.
A strong increase in NFκB activation was observed following TNFα treatment. The activation
was strongest in a 5 ng NLRC3 transfection setup. The unstimulated transfections did not respond
with an increased NFκB-Luc activity. The mock transfected controls showed a general response
to TNFα, which had to be considered as physiologic response.
4.4 Stimulation and downstream signaling
4.4.1 NLRC3 in response to TNFα stimulation
To investigate the fate and distribution of NLRC3 upon TNFα stimulation, an experiment with
different time points and an Western blot read-out was established (Fig. 4.13).
Fig. 4.13: Cell fraction of HEK-293 cells. HEK-293 cells were stimulated with 50 ng/ml TNFα for different time
periods and fractioned by differential centrifugation afterwards. The lysates were analyzed by Western blot. The blot
was incubated with α-NLRC3 and α-β-Actin as loading control.
Incubating the membrane with α-NLRC3 and α-β-Actin as control showed a strict localization
of NLRC3 in the cytosolic compartment. Normalizing the NLRC3 bands to the β-Actin bands
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showed a decrease of NLRC3 with time . The cell fractioning was successful leaving only marginal
amounts of β-Actin in the membrane fraction.
4.4.2 TRAF6 and NLRC3
TRAF6 is a member of the TNF receptor associated factor (TRAF) protein family, which takes
part in the downstream signaling of TNFα. The E3 ligase TRAF6 functions downstream of TNFR
and TLRs as an adapter molecule leading to the CD40-mediated activation of NFκB and c-Jun
[199, 200]. TRAF6 is known to be involved in the production of pro-inflammatory cytokines via
the TLR/MyD88/TRIF pathway and in the activation of NFκB signaling [201]. To investigate the
impact of TNFα stimulation upon NLRC3 signaling, a NFκB-Luc assay was established. A close
connection between NLRC3 and TRAF6 was published by Schneider et al. recently [51].
Fig. 4.14: Dual luciferase assay in HEK-293 cells. HEK-293 cells were transfected with a NFκB-Luc, a pRLTK-Luc
construct, and either 5 ng NLRC3 or an empty flag vector. The total amount of plasmid was kept constant by the addition
of an empty vector. Simultaneously, the samples were either transfected with TRAF6 siRNA (+) or control siRNA (-).
Half of the setup was stimulated with TNFα for eight hours, the other part was kept unstimulated. The data were gained
in two independent experiments, with each n=10 per column. Statistical significance was calculated by Student’s t-test.
Stimulating the cells with TNFα increased the NFκB response. Focusing on the effect of TRAF6
siRNA it was shown, that a down regulation of TRAF6 is accompanied by a significant increase of
the NFκB activity. A simultaneous transfection of TRAF6 siRNA and NLRC3-flag in HEK-293
cells significantly decreased the NFκB activity (Fig. 4.14). This experiment demonstrates, that the
signaling pathways of NLRC3 and TRAF6 are interconnected.
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4.4.3 Human peripheral blood mononuclear cells show distinct transcript patterns
after stimulation
Human peripheral blood mononuclear cells were isolated from a healthy donor, cultivated, and
stimulated. The cells were harvested, the RNA extracted, and transcribed to cDNA. The cDNA
was analyzed via TaqMan qRT-PCR.
Fig. 4.15: TaqMan qRT-PCR analyses of PBMCs. PBMCs were either kept unprimed or were pre-stimulated with
PMA/ionomycin (P/I). After 18 hours priming the main stimulus was added (LPS, PolyI:C, TNFα, IFNγ). Transcript
level for A NLRC3 and B TNFα were evaluated. The stimulation was carried out in two independent wells for each
treatment, quantification utilized two technical replicates each.
Responsiveness of PBMCs to a variety of stimuli was assessed on transcript level (Fig. 4.15).
NLRC3 transcript levels were upregulated especially after LPS, TNFα, and IFNγ stimulation (Fig.
4.15 A). The transcript level of NLRC3 were decreased after co-stimulation of P/I. P/I stimulation
alone did not alter NLRC3 expression. With respect to the TNFα transcript level it has to be
mentioned, that co-stimulation generally increased the transcript level (Fig. 4.15 B).
4.5 Nlrc3-/- mice do not exhibit a spontaneous phenotype
4.5.1 Basal phenotyping
The offspring of Nlrc3+/+ and Nlrc3-/- mice was alive and development appeared normal. Neither
an optical phenotype, nor differences in behavior and life span were detectable between WT and
KO. In a basal aging experiment four Nlrc3+/+ and five Nlrc3-/- mice were housed and fed ad
libitum. They all survived more than 18 month, outliving the observation period. For a basal phe-
notyping, organs with known Nlrc3 expression were sampled from sacrificed Nlrc3+/+ and Nlrc3-/-
mice and stained with HE (Fig. 4.16, 4.17).
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Fig. 4.16: Basal phenotyping of murine adrenal gland, spleen, and colon. Adrenal gland, spleen, and colon tissue
were HE-stained. The magnification is given for each pair of pictures. WT and KO are directly opposed for each organ
in both magnification steps.
Adrenal gland The tissue of the adrenal gland was composed of the inner medulla, engulfed
in the cortex, and finally covered by the outer capsule. The most obvious difference were less
dense packed chromaffin cells in the medulla of the KO animals. Several larger holes appeared,
which might be an artifact due to the cutting. The surrounding zona fasciculata seemed to be more
permeable, too (Fig. 4.16, 1st row).
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Fig. 4.17: Basal phenotyping of ileum, liver, and lymph nodes. Ileum, liver, and lymph node were HE stained. The
magnification is given for each pair of pictures. WT and KO are directly opposed for each organ in both magnification
steps.
Spleen A healthy WT spleen displayed two easily distinguishable patterns - the red and white
pulp. The white pulp appeared blue after HE staining, while the red pulp, a host to monocytes
[202], appeared red. The surrounding capsule commenced in a comparable thickness in WT and
KO samples, indicating no latent inflammation (Fig. 4.16, 2nd row).
Colon The sections showed the three clearly distinguishable parts of the colon structure, the outer
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muscularis, followed by a thin submucosa, and the inner mucosa. The mucosa consisted of villi
columnar cells including absorptive cells and the goblet cells. Goblet cells are glandular cells,
secreting mucin. All structures were identifiable in both, the WT and KO sections and did not
show any genotype-related abnormalities (Fig. 4.16, 3rd row).
Ileum A striking feature of this sections were the large crypts between muscularis and villi, ap-
pearing as intensively stained round structures. The Lamina propria mucosa was well structured.
There was no obvious disturbance in the KO samples compared to WT (Fig. 4.17, 1st row).
Liver The liver sections revealed a homogeneous structure of hepatocytes, being separated by
sinusoids. Hollow, round shaped structures were veins (Fig. 4.17, 2nd row).
Lymph node The encapsulated lymph node is mainly composed of two regions, the outer cortex
and the inner medulla with the medullary sinuses. According to the microscopic inspection no
alterations between WT and KO were visible (Fig. 4.17, 3rd row).
4.5.2 Murine blood analysis
As earlier experiments showed elevated blood glucose level in Nlrc3-/- compared to WT mice [data
not shown], a new glucose test and analysis of HbA1c levels was performed (Fig. 4.18).
Fig. 4.18: Basal blood glucose and HbA1c evaluation. Blood was drawn from eight freshly sacrificed mice of each
genotype (4 male and 4 female each) and analyzed for blood glucose level and HbA1c level.
The blood glucose level showed no significant differences between WT and KO. HbA1c is a long
term sugar proxy as hemoglobin is able to bind glucose to its N-terminus of the β-chain via
Amadori rearrangement. The value increases linear to the time of exposure to high sugar environ-
ment and persists for the liefetime of the erythrocyte. The HbA1c value is increased in diabetic
patients. In case of the Nlrc3-/- mice the HbA1c levels were significantly decreased compared to
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the WT. The mice did not show any other signs of diabetes, e.g. an abnormal water consumption.
Pregnancy may interfere with the HbA1c level, but is not applicable here, as the mice were kept
separated by gender. Malfunctions of the liver, were not identifiable by structural changes (Fig.
4.17). Dietary differences could be excluded as well, as all mice were fed with the same food
pellets. It might be hypothesized, that an increased red blood cell turnover of yet unknown reason
caused the genotype related differences.
4.6 Response of Nlrc3-/- BMDM to lipopolysaccharide stimuli
As the main stimulus for Nlrc3 activation remained unknown, a general LPS stimulation was
applied to determine the impact of Nlrc3 on the pro-inflammatory IL-6 (Fig. 4.19). Therefore
BMDMs were isolated from Nlrc3-/- and Nlrc3+/+ mice and stimulated with three different LPS
preparations (Invivogen, Sigma-Aldrich, and FZ Borstel, see Tab. 3.17) for 8 hours.
Fig. 4.19: Responsiveness of BMDMs to LPS stimulation. An IL-6 ELISA was performed to measure the IL-6 level
secreted by the BMDMs prior and after eight hours stimulation. Significance levels were evaluated by Student’s t-test.
The pro-inflammatory cytokine IL-6 was upregulated in all stimulated samples after 8 hours. To
further investigate the time-dependency, also with regard to different ILs, a second experiment on
BMDMs was performed. BMDMs were cultivated and stimulated with the ultrapure LPS provided
by the Research center Borstel. The transcript level of IL-2, IL-6, and IL-10 were monitored.
IL-2 transcript levels were below the detection limit. IL-6 transcripts steeply increased after 30
minutes stimulation, with values being significantly higher in KO cells. The IL-10 transcript levels
were increasing after 30 minutes as well, peaking after 60 minutes, to decrease afterwards (Fig.
4.20). To further assess the transcript regulation in BMDMs a new experiment was designed,
utilizing n=6 mice of each genotype. BMDMs were isolated and stimulated with three different
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Fig. 4.20: Transcript analysis in BMDM. Murine BMDMs were isolated from 3 Nlrc3+/+ (WT, hollow square) or 3
Nlrc3-/- (KO, filled triangle) mice and stimulated with LPS. The transcript level of A IL-6 and B IL-10 were quantified
via TaqMan assay in two technical replicates each. IL-2 was not detectable.
LPS for 2 to 8 hours, governed by an unstimulated control. IL transcript levels were assessed via
qPCR analysis. The results are depicted for the interleukins IL-1β, IL-6, and IL-10 in Fig. 4.21
and for IL-12, IL-18, and the murine IL-8 homologue CXCL1 in Fig. 4.22.
IL-1β levels were slightly higher in KO than in WT unstimulated BMDMs. This trend persisted
throughout the whole stimulation time, showing a stronger response to LPS from Sigma-Aldrich
and Borstel. The induction with the Sigma-Aldrich and Borstel LPS resulted in a 1000-time fold-
change after 8 hours, while the foldchange in Invitrogen LPS samples was lower. As a tendency
the induction seemed to peak between 2 and 8 hours to decrease afterwards (Fig. 4.21 A).
IL-6 levels were significantly higher in untreated KO cells. After LPS stimulation the transcript
level increased dramatically, promoted strongest by the ultra-pure Borstel LPS. In general were
the transcript levels, expressed as foldchange, significantly higher in KO cells (Fig. 4.21 B).
Although the transcript level of IL-10 were much lower than in case of IL-6 the general course
appeared to be similar. IL-10 transcript levels were slightly elevated in unstimulated KO cells and
were still exceeding the WT values after stimulation (Fig. 4.21 C).
The transcript level of IL-12β displayed a heterogeneous response to LPS stimulation. While a
general induction was clearly visible after LPS stimulation, peaking after 2 hours, KO and WT
samples were indiscriminative (Fig. 4.22 A).
IL-18 was the least inducible cytokine in this set. The transcript levels merely did not changed
after 2 hours of LPS stimulation. As a trend the WT seemed to transcribe lower amounts of IL-18,
being weakly significant after 2 hours of Sigma-Aldrich LPS stimulation (Fig. 4.22 B).
CXCL1 displayed the highest variation even in unstimulated cells, with a significant trend to
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Fig. 4.21: TaqMan analysis of LPS stimulated BMDMs. BMDMs were stimulated with three different LPS for three
different periods each. RNA was isolated, transcribed to cDNA, and analyzed via TaqMan. The cytokine expression of
A IL-1β, B IL-6, and C IL-10 was measured in unstimulated BMDMs and 2 and 8 hours after LPS stimulation. WT
is indicated by hollow squares, KO by black triangles. Six mice of each genotype were used. Significance level were
evaluated by Student’s t-test.
a higher transcript level in KO cells. The stimulation with LPS induced a boost after 2 hours,
extinguishing any significant difference between KO and WT (Fig. 4.22 C).
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Fig. 4.22: TaqMan analysis of LPS stimulated BMDMs. BMDMs were stimulated with three different LPS for three
different periods each. RNA was isolated, transcribed to cDNA, and analyzed via TaqMan. The cytokine expression of
A IL-12β, B IL-18, and C CXCL1 (murine IL-8 homologue) was measured in unstimulated BMDMs and 2 and 8 hours
after LPS stimulation. WT is indicated by hollow squares, KO by black triangles. Six mice of each genotype were used.
Significance level were evaluated by Student’s t-test.
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Fig. 4.23: Activation, responsiveness, composition, and IL-transcript level of murine mixed splenocytes. Murine
mixed splenocytes were extracted from four Nlrc3+/+ (WT, hollow square) and Nlrc3-/- (KO, filled triangle) mice each.
A Cell composition of mixed splenocytes was assessed by FACS analysis. B The activation of T cells included in the
mixed splenocytes was measured by FACS αCD25 staining. C Cell viability was tested by MTS assay. The transcript
level of D IL-2, E IL-6, and F IL-10 were quantified via TaqMan Assay (three mice per genotype, two technical
replicates). Significance levels were evaluated by Student’s t-test.
4.6.1 Murine splenocytes as in vitro model for immune cells
Mixed splenocytes were isolated from Nlrc3-/- and Nlrc3+/+ mice. The cell composition was eval-
uated, and cells were incubated with a set of stimuli quantifying activation by binding to α-CD25
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via flow cytometry. Additionally, a viability assay was carried out (Fig. 4.23).
The isolated splenocytes were composed of about 20 % T cells, and 40 % B cells. Up to
30 % of the cells were CD4+. While B cells were significantly increased in KO mice, CD4+ cells
were strongly decreased compared to WT mice (Fig. 4.23 A). Analysis of CD25 after stimulation
revealed a strong activation effect for 2C11, being a T cell activator by binding to the CD3ε of
murine T cells. In comparison to WT splenocytes, KO cells displayed elevated CD25 marker lev-
els (Fig. 4.23 B). Nlrc3-/- mice had a significant higher viability in nearly all tested stimulation
regimes. A stimulation or co-stimulation with P/I resulted in a lower viability, compared to un-
stimulated controls (Fig. 4.23 C). Additionally, a stimulation with LPS was conducted to achieve a
more detailed time resolution of the splenocyte response. Assessing the transcript levels of Nlrc3
and three of the major cytokines showed a decrease in IL-2 transcript levels, being stronger in WT
cells. The IL-6 increase was nearly insignificant and indistinguishable between WT and KO. The
transcript level of IL-10 increased slightly over time (Fig. 4.23 D-F).
4.7 Implication of NLRC3 in autoimmune and chronic inflammatory
diseases
4.7.1 Wegener’s granulomatosis/granulomatosis with polyangiitis
Wegener’s granulomatosis (WG) is an autoimmune disease resulting in early stages in a local
inflammation of the nasal mucosa [203]. Expression level of the NLRC3 protein were measured
in patient samples (Fig. 4.24).
Fig. 4.24: NLRC3 protein level and relative mRNA expression in Wegener’s granulomatosis. A Western blot of
NLRC3 and other proteins of interest in samples from normal controls (NC) and WG patients (WG). B Relative mRNA
expression of NLRC3 transcripts in NC, WG, and chronic rhinosinusitis with nasal polyps (CRS) patients. Box plots
represent the 25th, 50th, and 75th percentile, whisker plots display 5th and 95th percentile. Asterisks highlights transcript
which resulted in a p-value ≤ 0.05 and false discovery rate of the induction of ≤ 5 % when compared with WG.
While no histological abnormalities were detectable in biopsies taken from WG and normal con-
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trols (NC) the NLRC3 protein level differed significantly. NLRC3, detected by the α-NLRC3 an-
tibody showed a decrease in the protein levels of WG patients. The transcription levels of mRNA,
assessed by qPCR analysis supported this trend (Fig. 4.24 B). The differences were based on
specific disease associated mechanisms as general inflammation markers were not affected [203].
Several publications are referring to WG now as granulomatosis with polyangiitis (Wegener’s)
[204].
4.7.2 Crohn’s disease
As NOD2, a member of the NLR family group, is highly relevant for Crohn’s disease (CD) a
qPCR test was performed on relevant samples, testing for altered NLRC3 expression. Biopsies
from non-inflamed tissues were compared for 18 Crohn’s disease, 11 Ulcerative colitis (UC), 15
diseased controls (DC), and 28 hospitalized normal (HN) patients. NLRC3 in CD was 1.3 times
elevated compared to NC (p=0.0324) and 1.8 elevated with respect to inflamed disease specific
controls (p=0.0315).
Fig. 4.25: Quantification of NLRC3 transcript level in IBD patients. Non-inflamed samples of Crohn’s disease (CD),
Ulcerative colitis (UC), diseased controls (DC), and hospitalized normal (HN) patients were analyzed via TaqMan. All
samples were age and gender matched.
4.8 Impact of acute dextran sodium sulfate induced colitis on WT and KO
mice
An acute murine colitis was induced by 4 % DSS. The experimental setup included only male
Nlrc3+/+, Nlrc3-/- mice, and an untreated Nlrc3-/- control group. The course of disease was scored
via the proxies united in the disease activity index (DAI). Additionally, the mice were scored
endoscopically on the final day. After sacrificing the mice the colon length was measured and nor-
malized to the body weight and spleen weight was determined. Serum was sampled and selected
organs were prepared for histological staining.
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4.8.1 DSS-induced colitis heavily affects the colon
Prior to sacrificing the mice an endoscopic examination was carried out, resulting in the pictures
displayed in Fig. 4.26 and the MEICS score as shown in Fig. 4.28 B.
Fig. 4.26: Selected exemplary pictures of murine coloscopy. Prior to sacrificing the mice, they were anesthetized and
examined by coloscopy. The coloscopy data were the basis for the MEICS score. Pictures shown are demonstrating the
most striking features found during the endoscopy of all mice in the experiment.
An exemplary colon from a water treated control mice is shown in the control column (Fig. 4.27).
The mucosa was found to be intact, the stool was formed and no plaques were seen. The blood
vessels appeared normal. A different state was observed in the DSS treated mice. While the stool
consistency was more like a smear several white fibrin patches were visible. Blood vessels were
prominently seen in several directions and the mucosa was strongly eroded. As shown in Fig. 4.28
D the colons of DSS treated mice were significantly shortened. The exact measurements of colon
length is given in Tab. 4.3.
A significant shortening of colon was observed when comparing water and DSS treatment. Both
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Fig. 4.27: Selected exemplary pictures of murine colons. The colon was flushed and measured. The proximal end is
on the left side.
Tab. 4.3: Measured colon length of animals included in this study. Length is given in mm. Values in brackets were
measured in animals which died during the experiment. Those values were not considered for Fig. 4.28 D.
genotype colon length [mm]
WT 55 47 52 50 55 50 51 42
KO (54) 50 (65) 53 (51) 58 50 70 60
Control 78 103 88
genotypes were affected, displaying additional heavily inflamed distal parts and occasional patches
of clotted blood.
4.8.2 DAI and MEICS score
The disease progression was monitored via DAI and finally via MEICS. Increasing index values
represent a more severe disease progression. The results are summarized in Fig. 4.28.
While the untreated animals remained visibly healthy during the experiment, both treated groups
showed a significant onset of disease at day three. The onset of disease was comparable in WT
and KO during the first days, worsening significantly for Nlrc3-/- animals on day six (Fig. 4.28 A).
The experiment was stopped on day eight, with most mice reaching the critical cut off bodyweight
of 75 % as depicted in Fig. 4.28 C. An endoscopic examination of the mice prior to scarification
showed a significant difference between the DSS treated animals and the control, but not between
WT and KO mice (Fig. 4.28 B). As a proxy for DSS-induced disease severity colon length was
measured. After flushing the colon, it was measured and the length normalized to the body weight
on day eight. While the untreated mice displayed a colon length of up to 103 mm, the colon was
shortened down to 42 mm in DSS treated mice independent of the genotype.
Weighting the spleen resulted in weights between 34.9 and 106.1 mg, but gave no strict trend or
significant different results between the genotypes or the treatment (Fig. 4.28 E). Additionally,
the spleen length was determined, resulting in sizes between 12 - 17 mm. A significant difference
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Fig. 4.28: DAI and MEICS score of acute DSS colitis. A The disease activity index (DAI) is an artificial numeric
score, summed up from evaluation of weight loss, stool consistency, and intensity of rectal bleeding. The DAI was
assessed on a daily basis. B The modified murine endoscopic index of colitis severity (MEICS) consists of five param-
eters and was assessed according to Becker et al. [187]. C Body weight was measured daily and is expressed in percent
normalized to individual starting weight. D Colon length was measured and normalized to starting bodyweight of the
respective mouse. Additionally, the spleen was weighted E and measured along its largest extent F. Initially 8 WT, 9
KO, and 3 Ctrl.-KO mice were used in this experiment. Due to disease progression, technical limitations or experimen-
tal procedures do not all graphs contain data from each mouse. All values of Nlrc3+/+, Nlrc3-/-, and an untreated Nlrc3-/-
control group were corrected for statistical outliers and were finally analyzed by Student’s t-test.




4.8.3 Nlrc3+/+ mice are less affected of tissue damage and infiltration by immune
cells
To visualize morphological changes in colon and ileum, microsections of fixed tissues were stained
with HE. A HE score was evaluated in a blinded manner to grade the severity of tissue damage
(Fig. 4.29 A). Therefore the two proxies "infiltration of immune cells" and "tissue damage" were
scored with zero (unaffected) to three points (heavily affected) each. Summing up the points for
each sample gave the HE score and therefore an indicator of the severity of DSS-induced colitis
[205].
Fig. 4.29: Histological scoring of HE stained colon sections. The colon was flushed and cut longitudinally. After
rolling it from distal to proximal, fixation in 10 % formalin, and embedding in paraffin, it was cut and stained with HE.
A The scoring was performed in blinded manner, taking mucosal damage and invasion of immune cells into account.
HE stained sections were microscopical inspected and scored, giving 0-3 points each for mucosal damage and immune
cell invasion, with 0 being a non visible and 3 being a thoroughly visible effect. A Student’s t-test was performed. B-D
Exemplary microscopic pictures were taken for B Ctrl., C WT, and D KO , each showing a 5x magnified overview and
a 10x magnified detailed photo. Due to disease progression, technical limitations or experimental procedures were not
all mice represented in the graph.
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Comparing the HE score of Nlrc3+/+ and Nlrc3-/- mice showed a significant lower score for the
WT. Both scores were highly elevated when compared to the untreated control mice (Fig. 4.29 A).
The numerical scoring is based on microscopic evaluation. In Fig. 4.29 B-D exemplary pictures of
the three groups are shown. Compared to the untreated controls in Fig. 4.29 B, both DSS treated
samples displayed a severe change in cellular structure and organization. While the crypts were
neatly aligned in the control, they seemed to lack any structure in the DSS treated samples. Crypts
were closed or displayed no regular structures at all. Mucosal surfaces were eradicated and the
lamina propria was infiltrated by immune cells. Additionally, some crypt abscesses were found.
Those structures were manifested mostly in the distal part of the colon and were significantly
increased in the Nlrc3-/- samples. As seen in Fig. 4.30 those abscesses were characterized by a
decrease of goblet cells and a reduced cell count per structure compared to healthy crypts.
Fig. 4.30: Crypt abscesses in colon tissue of DSS treated Nlrc3-/- mice. The colon was flushed and cut longitudinally.
After rolling it from distal to proximal, fixation in 10 % formalin, and embedding in paraffin, it was cut and stained with
HE. A The vacuolar like structures were counted in a sample blinded manner in all samples suitable. Some samples
had to be excluded due to eradicated colon structure or cutting artifacts. B Two microscopic images are demonstrating
the observed structures. The left side shows the general appearance in the distal colon. The 10x close-up on the right
reveals the detailed morphology. Due to disease progression, technical limitations or experimental procedures were not
all mice represented in the graph.
4.8.4 Serum and transcript level of interleukins
Additionally to the morphological analysis of tissue sections and organs, several molecular analy-
ses were carried out. Murine blood was gained by coronal puncture. After clotting and centrifuga-
tion the serum was snap frozen. Due to the limited volume of serum available, three ELISA were
performed, quantifying the serum level of IL-6, CXCL1, and IL-10 (Fig. 4.31).
The serum levels of neither IL-6 nor IL-10 were significantly altered comparing either WT vs. KO
or the treatments. The same held true for a comparison of samples from DSS treated animals and
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Fig. 4.31: Serum analysis of DSS treated mice. Serum concentrations of interleukins were measured by ELISA. All
levels are given in pg/ml, Mean and standard deviation are indicated. A IL-6, B CXCL1, and C IL-10 levels of Nlrc3+/+,
Nlrc3-/-, and an untreated Nlrc3-/- control group were assessed. A Student’s t-test was performed after calculating values
distribution and correcting or outliers. Due to disease progression, technical limitations or experimental procedures were
not all mice represented in the graph.
the water control. The CXCL1 level was significantly increased in Nlrc3-/- mice treated with DSS.
As the secreted interleukin levels were quite low, spleen, colon, and mesenchymal lymph node
were tested for their IL-6 and IL-10 transcript level.
Fig. 4.32: TaqMan analysis of DSS tissue cDNA. RNA was isolated from colon, spleen, and mesenchymal lymph
node (mln), processed and analyzed by TaqMan. Transcript levels of A-C IL-6 and D-F IL-10 were assessed in samples
of DSS treated Nlrc3+/+ and Nlrc3-/- mice, as well as in mice of the untreated Nlrc3-/- control group. A Student’s t-test
was performed.
In general only small ∆Ct values were gained (Fig. 4.32). The IL-6 level were increased in all
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DSS treated samples compared to the untreated KO, revealing no significant difference between
the treated WT and KO (Fig. 4.32 A-C). The mean value of the KO samples exceeded the WT
values. The IL-10 levels were increased in all DSS treated samples as well, showing no distinctness
between WT and KO (Fig. 4.32 D-F).
Fig. 4.33: NFκB activation in DSS treated Nlrc3-/- knockout mice. Mice were treated with DSS. After scarification
the colon was rolled from distal to proximal and prepared for histological staining. Staining was carried out by using
an α-NFκB antibody, being detected by the DAB system. Pictures were taken in two different magnifications, each
comparing the secondary antibody only control (left) with the antibody based staining (right).
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4.8.5 NFκB is upregulated in DSS treated mice
Following the luciferase results, showing an impact of NLRC3 on the NFκB pathway, colon sec-
tions of DSS treated mice were stained with an α-NFκB antibody, using the DAB system. The
comparative results are depicted in Fig. 4.33.
The untreated controls exhibited the weakest expression of NFκB in the histological staining.
Stained colon microsections from DSS treated mice showed a general increase in NFκB, obviously
strongest in the KO samples (Fig. 4.33). A treatment without the primary antibody was used as
control. Thus the blue counter staining was predominant, showing no unspecific staining of the
DAB system. As NFκB was nearly ubiquitous expressed in cells a negative control including a first
antibody was not suitable. All results are therefore to be seen in relation to the control animals.
4.8.6 Mitochondrial stress markers are not affected in colonic tissueafter DSS
treatment
Consistent with the idea of a mitochondrial stress reaction and a potential impact of unfolded
protein response governed by Nlrc3 the transcript level of three described proxies (grp78, cpn60,
and pkr [206]), were quantified via SYBRGreen analysis (Fig. 4.34).
Fig. 4.34: SYBRGreen analysis of DSS tissue cDNA. RNA was isolated from colon and ileum, processed, and an-
alyzed by quantitative qPCR. Transcript levels of pkr, cpn60, and grp78 were assessed. A-C Colon and D-F ileum
samples of Nlrc3+/+, Nlrc3-/-, and an untreated Nlrc3-/- control group were analyzed. A Student’s t-test was performed.
Comparing the expression level of grp78 between WT and KO did not reveal any significant dif-
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Fig. 4.35: TRAF6 staining in DSS treated colon samples. Mice were treated with DSS. After scarifying, the colon
was rolled from distal to proximal and prepared for histological staining. Staining was carried out by using a α-TRAF6
antibody, being detected by the DAB system. Pictures were taken in two different magnifications, each comparing the
secondary antibody only control (left) with the antibody based staining (right).
ferences between neither both genotypes nor the genotypes and the controls. The variation was
remarkably low in colon samples, while it showed an intersting trend in ileum. The grp78 level
were generally lower after DSS treatment, independently of the genotype, although the level in
KO tended to be lowest. With regard to cpn60 level it has to be mentioned, that colon samples
seemed to be unaffected, while the level were decreased in DSS treated ileum cells. Nevertheless
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did no statistical significances occur. The pkr levels were the lowest in the whole experiment with
regard to their ∆Ct value. Neither the level in colon nor in ileum samples showed a statistically
relevant difference.
4.8.7 TRAF6 is diminished in DSS treated mice
As TRAF6 is a member of the downstream signaling in the NFκB pathway it was tracked by
histological staining in microsections from DSS mice.
The TRAF6 control showed a widely distributed staining. Compared to the control the villi and
muscularis were stained brownish, indicating a TRAF6 localization. The intensity of staining de-
creased in WT an even more in KO samples (Fig. 4.35). The crypt abscesses shown in Fig. 4.30




5.1 NLRC3/Nlrc3 is localized in immune relevant tissues
The expression level of NLRC3/Nlrc3 were assessed in human and murine cDNA samples (Fig.
4.2). Human NLRC3 was found to be highest expressed in tonsil, leukocytes, thymus, lymph
node, and spleen (Fig. 4.2 A). These findings are supported by the study of Yin et al. although
they founds a markedly higher expression in placenta cDNA [207].
Results shown in Fig. 4.1 and 4.2 B present an extended picture for mice. Immune relevant organs,
such as lymph node, thymus, and spleen show an increased expression of Nlrc3. These findings are
in concordance with the results from human samples, with slight differences according their rela-
tive values. The high expression in thymus is supported by earlier findings, describing NLRC3 as
a negative regulator for T cells [50]. Combined with a low expression of NLRC3 in hematopoietic
stem cells the results suggested that NLRC expression occurs in cells that have undergone thymic
maturation and induction. Samples obtained from organs of the gastrointestinal tract display a low
expression of NLRC3/Nlrc3 in both, human and mouse. The respective organs were not assessed
in the gene microarray published by Conti et al. [50]. Additionally, only weak NLRC3 expression
was measured in healthy brain samples, which supports the theory of suppressed NLRs in immune
privileged sites [208].
Comparing these results to previously published date by Conti et al. reveals a high overlap in
mouse data. The human samples exhibit a comparable NLRC3 expression profile with additional
high NLRC3 transcript levels in leucocytes, spleen, and tonsil. Latter both were not tested by Conti
et al.. In general are the expression level of NLRC3 in bone marrow and lymph node samples
higher in the experiments conducted for this thesis. Higher NLRC3/Nlrc3 transcript levels were
found in types of immune relevant tissues, indicating a lack of NLRC3 in most other tissues.
Differences between the current data and those found by Conti et al. may occur due to different
sampling strategies. The data in this thesis are based on pooled cDNA samples, while Conti et al.
mined different microarrays and compared them to a murine profile to validate the data sets. Their
data might be stratified due to the fact, that every sample originated from a different individual,
bearing the danger of different health/immune states of each donor. This indicates the importance




The NLRC3 epression in kidney and spleen is matched by an earlier study in channel catfish Ic-
talurus punctatus [48]. Sha et al. additionally found increased level in the intestine, a feature which
seems to be specific for fish. This might indicate a difference in NLRC3 distribution between sys-
tematic classes, such as mammalians and pisces. Overall, tissues involved in the generation of
immune relevant cells seem to express NLRC3/Nlrc3.
5.2 NLRC3 in mitochondria associated immune functions
To address localization and the functional role of NLRC3 in cell signaling pathways, HEK-293
cells were used, which express endogenous levels of NLRC3 (Fig. 4.3 A). Additionally, the ad-
herent HEK-293 cells allow the transfection of recombinant NLRC3 and luciferase-based reporter
assays and a reliable visualization in microscopic studies. HeLa cells were used to confirm the
microscopic results.
In Fig. 4.4 the localization of endogenous NLRC3 in HEK-293 cells, as well as in primary culture
of PBMCs, was detected in the cytosolic fraction only. This finding was confirmed by microscopy
in antibody-tagged NLRC3 coverslip staining (Fig. 4.6). One of the general features of NLR pro-
teins seems to be their cytosolic or intracellular localization [209]. Y2H approach revealed the
mitochondrial protein Mitofilin/IMMT as a potential interactor for NLRC3. The cytosolic localiza-
tion of NLRC3 would allow an interaction with mitochondria. During a MS/MS analysis NLRC3
was detected in mitochondrial lysates (Fig. 4.10).
5.2.1 Mitochondria in innate immunity
Mitochondria are considered to be crucial hubs for the immune system. An overview of mitochon-
drial associated proteins involved in innate immunity is given in Tab. 5.1. NLRX1 has been the
only member of the NLR family known to localize to mitochondria so far. Although the N-terminal
HA-tagged version of NLRX1 was not observed inside the mitochondria, most likely due to an
additional tag, it was proposed to interact with mitochondria via a mitochondria associated viral
sensor (MAVS) [210]. MAVS has been shown to have a critical effect in the activation of antiviral
host response, by spanning the outer mitochondrial membrane and activating the NFκB pathway
[211]. A MAVS mediated apoptosis was shown, including viral strategies to evade apoptosis by
inhibiting host response [212]. This interaction might prove valuable for further NLRC3 studies




Tab. 5.1: Mitochondrial proteins associated with immune related signaling. ASC: Apoptosis-associated speck-
like protein containing a CARD; c: cytosol; cs: cell surface; ECSIT: Evolutionary conserved signaling intermediate in
Toll pathway; IFN: Interferon; IRGM: Immunity-related GTPase family M protein; loc: localization; MAP: Mitogen-
activated protein; MAPK: MAP kinase; MAVS: Mitochondria associated viral sensor; MDA5: Melanoma differentia-
tion associated gene 5; NEMO: NFκB essential modifier; RIGI: Retinoic acid-inducible gene gene I; RLR: RIGI like
receptor; ROS: Reactive oxygen species; tl: translocates; TANK: TRAF family member-associated NFκB activator;
TBK: TANK binding kinase; TLR: Toll like receptor; TRAF: TNF receptor associated factor; UQCRC2: Ubiquinol-
cytochrome c reductase core protein II.
PRR trigger adapter signaling loc source
NLRX1 indirect? UQCRC2 MAVS tl [210, 213]
NLRP3/ mitoROS? ASC Inflammasome/ [214, 215, 216]
NALP3 Caspase-1
RIGI like/ viral MAVS TRAF3&6/ c [211, 217, 218, 219]
MDA5 ss/ds RNA TBK1-NEMO/
NFkB
TLR1/2/4 ROS TRAF6/ECSIT NFkB, MAPK cs [220]
IRGM intracellular cardiolipin HMGB1 [221, 222]
pathogens
To evaluate whether NLRC3 interacts with the mitochondrial protein IMMT, a three-step micro-
scopic sequence was established. As shown in Fig. 4.6, HEK-293 cells were transfected with flag-
tagged NLRC3. The α-flag antibody detected the overexpressed flag-tagged NLRC3, while the
α-NLRC3 antibody detected both the endogenous and overexpressed NLRC3. The nucleus and
mitochondria were stained with DAPI and Mitotracker, respectively. The merged pictures showed
an overlap of the mitochondrial and NLRC3 signals indicating the spatial localization of NLRC3
with mitochondria. To confirm the potential interaction between NLRC3 and IMMT, a specific
α-IMMT antibody was used. The perfect overlap of the IMMT and mitochondrial staining (Fig.
4.7) demonstrate the specificity of the detection. An overlap of Mitotracker and NLRC3 signals
was detectable. These finding were confirmed in transfected HeLa cells (Fig. 4.8). A higher reso-
lution and a correlation analysis were gained by CLS microscopy (Fig. 4.9). The merged picture
indicates a broad overlap of the NLRC3-, IMMT- and Mitotracker signals. A second approach
without Mitotracker was used for a correlation analysis, further confirming the overlap of signals.
Co-immunoprecipitations performed, did not show an interaction of NLRC3 and IMMT, probably
due to technical limitations of the α-NLRC3 antibody (Fig. 4.5). A tandem mass spectrometry
(MS/MS) analysis of the mitochondrial lysates was conducted, confirming NLRC3 in mitochon-
dria lysate. However, in the same study NLRC3 was not detected in the α-NLRC3 immunopre-




The difficulty to show a direct interaction between NLRC3 and mitochondria raises the possibil-
ity of an induced re-localization. Upon stimulation, cytosolic NLRC3 might be recruited to the
mitochondria. After TNFα stimulation NLRC3 did not migrate to the membrane, but decreased
over time in the cytosolic compartment (Fig. 4.13). No accumulation of NLRC3 was detected
in the membrane fraction. The close spatial proximity of NLRC3 and IMMT may involve a yet
unknown adapter similar to the interaction of NLRX1 (Tab. 5.1). Factors like mitochondrial mem-
brane potential and conformational changes after ligand binding might influence this translocation
as well [210, 223].
Subsequently, in a bioinformatic approach probabilities of mitochondrial localization of NLRC3
were calculated. These in silico analyses predicted low values for the human NLRC3 isoforms
(max. 0.11), but increased probability values for the murine Nlrc3 isoforms 3 and 4 (Tab. 4.2). A
different analysis by Moore et al. calculated lower values for mitochondrial localization. As the
exact location of NLRC3 within the mitochondria or mitochondrial complex remains unknown it
is interesting to note significant differences in the mitochondrial import probability of the Nlrc3
isoforms. While the human variants and the murine consensus isoform were calculated to have a
low propability to be imported into mitochondria, are the results for isoform 3 and 4 much more
promising. Both isoforms are truncated and are lacking the NACHT domain. This is true for the
murine isoform 5 as well. Taking the electric charge of the isoforms into account does not solve
the problem either. It becomes obvious, that mitochondrial targeting is an interplay of a variety
of different molecular and biophysical factors [190, 193]. Additionally, the integration of NLRC3
into the outer membrane of the mitochondria might be a feasible mechanism to enable NLRC3
and IMMT interaction [92].
5.2.1.1 Supramolecular mitochondrial structures
Several α-NLRC3 Western blots showed additional and distinct bands at high molecular weight
(>250 kDa) in cellular lysates following stimulation [data not shown]. Although NLRC3 is not
known to multimerize, dimerization is a common feature in members of the NLR family [36].
High molecular weight complexes have been published for mitochondrial constituents, such as
IMMT [82, 224]. To determine whether the high molecular weight protein bands correspond to
complexes of IMMT with NLRC3, the lysates were analyzed by MS/MS. Comparable to a variety
of recently described signalosomes, an IMMT containing multi-protein complex would offer sev-
eral possibilities for NLRC3 association. Matrix and membrane spanning elements could bridge
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the spatial distance, while functional complexes, such as Optic atrophy 1 (Opa1) and DISC could
provide effector activities. A yet hypothetical model could be considered as followed:
The coiled-coil-helix-coiled-coil-helix domain containing protein 3 (Chchd3) is a peripheral pro-
tein of the inner mitochondrial membrane facing the intermembrane space. It closely interacts
with the IMMT and Opa1, which are both located in the mitochondrial cristae and are involved in
cristae morphology [80, 91, 225]. Downregulation of those proteins leads to mitochondrial fission
and christae morphology loss [80, 84]. This complex interacts with Sam50, being an outer mito-
chondrial membrane protein regulating import [224]. As Chchd3 has been proposed as a protein
that preserves cristae integrity and mitochondrial stabilization, it would be an ideal interaction
partner for an NLRC3 mediated signaling, relayed through IMMT. Chchd3 has been shown to be
part of a 340 kDa mitochondria organizing complex that has not been fully sequenced yet [226].
A variety of human pathologies are associated with alterations of these complexes, ranging from
Epilepsy to diabetic cardiomyopathy [82, 227, 228]. The MS/MS results presented in this thesis
did not identify a complex, neither in the lysate nor in the pull down assay. This indicates the
need of further effort to induce and stabilize the high molecular weight complexes in order to
characterize them.
5.2.1.2 Mitochondrial unfolded protein response (mtUPR)
The mtUPR is characterized as a cellular stress response activating nuclear-encoded mitochondrial
chaperone genes in order to restore organelle protein homeostasis [229]. Similar to the UPR gen-
erally known from the ER, the mtUPR facilitates the refolding of mis- or unfolded proteins by the
use of heat shock Hsp70 family members. The mitochondrial matrix includes chaperones for the
general import and folding of proteins. Failures in this machinery might be corrected by proteases
in the inner membrane by degrading misfolded proteins [230]. This process can be modified ac-
cording to the needs of the cell. In this cause, the mitochondrial import efficiency is monitored
as a proxy for mitochondrial overall performance [231, 232]. However, the complete signaling
pathway is still under investigation. In a first attempt to unravel the molecular processes, an ER
targeting stress test was performed. The ERSE was cloned into a dual luciferase system. ERSE is
one out of three cis-acting elements which are capable of binding the transcription factor ATF6
[196, 233]. ER bound molecular chaperones are activated downstream to relieve the UPR burden.
As shown in Fig. 4.11, HEK-293 cells were transfected with an ERSE-promoter responsive lu-
ciferase. The effect of NLRC3 overexpression and stimulation with either TNFα or tunicamycin
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was quantified. Tunicamycin is a known stressor and inducer of UPR, which ultimately can lead
to apoptosis [234, 235, 236]. Results show that tunicamycin stimulation successfully induces the
ERSE activity. Additionally, a significant increase in ERSE activity in the NLRC3 overexpressing
cells was observed (Fig. 4.11). An upregulated activation of ERSE reflects the physiological cell
response to decide upon the cell fate. Depending on the downstream signaling the cell may either
upregulate molecular chaperones to counteract unfolded protein response, or activate apoptotic
pathways, when the unfolded protein burden overpowers the repair mechanisms of the cell [198].
Overexpressing NLRC3 alone does not induce ERSE. In combination with a stressor like tuni-
camycin is the ERSE promoter activiy significantly increased. An increased NLRC3 level leading
to higher ERSE activation may therefore result in a protective function of NLRC3.
The hypothesis of NLRC3 being involved in mitochondrial apoptotic processes is further sup-
ported by the fact that CARD domains have been originally described to be in close relation to
mitochondria dependent apoptotic signaling [237]. Furthermore, the translocation of the TNFα re-
ceptor 1 (TNFR1/CD120a) triggered by TNFα administration to mitochondria has been observed
[238]. This is of importance as the DISC formation is TNF dependent and TNFα decreases the
cytosolic NLRC3 expression (Fig. 4.13; [239]). Further in vivo studies of Nlrc3 effect on mtUPR
are discussed in chapter 5.6.
5.3 NLRC3 is involved in central immune signaling pathways
5.3.1 NLRC3 is involved in the NFκB signaling pathway
HEK-293 cells overexpressing different levels of NLRC3 and stimulated with TNFα had an in-
creased NFκB reporter gene activity. NLRC3 transfections were performed with 10-fold lower
DNA than used by Conti et al. which should keep the effect on destabilizing luciferin to a min-
imum and mimic a more physiological range [50, 68]. A notable increase in NFκB activity in
response to TNFα and overexpression of NLRC3 was observed. Increasing the amount of NLRC3
showed the contrary effect by decreasing the NFκB activity (Fig. 4.12). The results suggest that
NFκB activation is governed by a threshold of NLRC3 expressed and a resulting negative feedback
loop.
Conti et al. showed a decrease of NFκB reporter activity with increasing NLRC3 level. Their time-
course kinetics showed a reduced degradation of IκBα after overexpression of NLRC3 demon-
strating that NLRC3 may negatively regulate T cells via the canonical NFκB pathway [50]. An
increasing IκBα level in a time-course stimulation study indicated a downregulation of the NFκB
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pathway in the presence of NLRC3 [51]. The validity of luciferase assays was questioned by Ling
et al., who stated that the overexpression of NLRC3 resulted in an artificial inhibition of NFκB
[68]. To address this concern we employed in this study a dual luciferase assay with a second
luciferase under a thymidine-kinase promoter of Herpes simplex virus.
5.3.2 NLRC3 mediated NFκB signaling pathway is modulated by TRAF6
Rising evidence suggests a close crosstalk between TLR and NLR pathways, although it still re-
mains poorly understood. Of special interest is a recently published paper by Schneider et al.,
showing that NLRC3 inhibits the K63-ubiquitination of TRAF6 and the TLR mediated NFκB
signaling [51]. Experiments showed, that the overexpression of 5 ng NLRC3 during a TNFα stim-
ulation increases the NFκB promoter activity. Increasing the amount of NLRC3 led to a contrary
result (Fig. 4.12). The activation of the NFκB promoter could be generally shown in Fig. 4.14, too.
Interestingly, the presence of TRAF6 siRNA interferes with this result. As TRAF6 is known to be
an activator of NFκB, one would expect an additive effect of NLRC3 and TRAF 6 [201]. Never-
theless, in the experiments presented here is the NFκB promoter activity increased, when TRAF6
is downregulated. This holds true for experiments with and without overexpressed NLRC3. Addi-
tionally, the normalized activity in samples containing NLRC3 and TRAF6 siRNA is significantly
lower than in samples containing TRAF6 siRNA and a mock vector (Fig. 4.14).
A downregulation of TRAF6 mediated NFκB signaling has been described in connection with an
Epstein-Barr virus infection or microRNA miR-146 transfection [240, 241]. Schneider et al. ob-
served an inhibition of TLR mediated NFκB activation by NLRC3, proposing a negative feedback
loop. Still, the significant difference without overexpressing NLRC3 is not answered. Those ef-
fects were not significantly detectable in unstimulated cells (Fig. 4.14). An upregulation of NFκB
in response to TNFα stimulation was expected and the effect mentioned above might be the result
of the TRAF6 and NLRC3 interplay, which is not fully understood yet. There is an apparent over-
lap in the signaling of TLRs and NLRs converging at the same signaling cascades [242, 243, 244].
This convergence may either potentiate the signals or trigger a common inflammatory response to
different stimuli. Additionally, TRAF6 forms the linkage between the TLR receptor and the evo-
lutionary conserved signaling intermediate in TOLL pathway (ECSIT) [245]. TRAF6 translocates
to the mitochondria upon activation resulting in mitochondrial ROS and localization of ECSIT to
mitochondria where it is crucial for the assembly of complex 1 of the respiratory chain [146, 220].
It has been shown that TRAF6-∆T mice displayed an increased IL-17 level during DSS-induced
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colitis, indicating a beneficial effect on disease progression in absence of TRAF6 [246]. IL-17 is
mainly produced by T cells in the lamina propria and has a protective effect by inducing tight
junctions and mucin expression [247, 248].
A Y2H screen and Co-immunoprecipitation [data not shown] did not reveal a direct interaction
between NLRC3 and TRAF6 which is confirmed by others [51]. A histological staining shown in
Fig. 4.35 was performed in sections of intestinal tract of Nlrc3-/- mice after an acute DSS colitis.
The results suggest a decrease of TRAF6 in Nlrc3-/- mice after colitis. The strong TRAF6 staining
in the untreated control, which were mainly located at the villi surface, was not detectable in the
DSS treated Nlrc3-/- mice. This may be due to the heavily rearranged colonic structure. Overall,
the DSS-treated mouse show an increased TRAF6 level in wildtype Nlrc3+/+ mouse tissues and
decreased level in Nlrc3-/- samples. These findings are supported by recent work from Shen et al.,
who showed that TRAF6 expression is significantly increased in serum, PBMCs, and inflamed
intestine mucosa of IBD patients [249].
Besides the in vivo data from DSS colitis experiments TRAF6 was assessed in in vitro cell culture
experiments. Dual luciferase assays were conducted with expression of NLRC3 and knockdown
of TRAF6 via specific siRNA. The results are shown in Fig. 4.14. As expected, the normalized
activity of the NFκB-Luc reporter was increased in response to TNFα stimulation. In TNFα stim-
ulated HEK-293 cells, a knockdown of TRAF6 upregulates NFκB, an effect which is significantly
decreased by the addition of NLRC3.
Unstimulated cells showed the same trend although less notable. The results indicate that the
overexpression of NLRC3 enhances the NFκB downregulation. The general impact of NLRC3
on the NFκB pathway was shown to be dependent on the amount of NLRC3 overexpressed (Fig.
4.12). High amounts of NLRC3 downregulate NFκB, which is in concordance with the hypothesis
by Schneider et al., that NLRC3 inhibits TRAF6 mediated NFκB signaling. Lower amounts of
NLRC3 seem to activate NFκB signaling. The main discrepancy between studies was found when
comparing the basal GFP-luciferase assays with the TRAF6 knockdown. Overexpressing even low
amounts of NLRC3 seems to decrease the NFκB signaling. This effect may occur due to different
tags, although the findings by Conti et al. seemed to be less affected [50]. In the results presented
here, a TRAF6 knockdown led to an increase in NFκB. Combining a TRAF6 knockdown with
a NLRC3 overexpression resulted also in a decrease of NFκB activity. This combination might




The mediation of interleukin level is of utter importance in a regulated cell response and aims at
re-establishing homeostasis. An interleukin level is a suitable proxy to determine the current state
of an inflammatory process and to identify variations caused by genetic knockouts. Experiments
in this thesis utilized bone marrow derived macrophages, mixed splenocytes, and serum from DSS
treated animals to study interleukin levels. The in vivo studies are discussed in subsection 5.6.3.
BMDMs are widely used for immunological studies as they exhibit a long lifespan, yield high
RNA/protein levels, high homogenity, and a strong proliferative capacity [185, 250].
The BMDM based stimulation experiments rely on a LPS concentration of 100 ng/ml incubated
for two to eight hours to assess early and late responses. The induction of NFκB in response to
LPS (10 µg/ml) within 0.5 h has been shown for cell lines, indicating the temporally framework for
these experiments [145]. LPS of different quality grades was used - LPS from the FZ Borstel and
Sigma-Aldrich (Tab. 3.17). First is ultra pure and considered to solely activate the TLR4 pathway,
while the less pure Sigma-Aldrich preparations might provide low amounts of alternative stimuli.
5.4.1 Pro-inflammatory cytokines are elevated in Nlrc3-/- BMDMs
All LPS preparations applied induced an IL-6 secretion in WT and KO (Fig. 4.19). Transcript
levels of the pro-inflammatory cytokines IL-1β, IL-6, and CXCL1 were increased (Fig. 4.20, 4.21,
and 4.22).
IL-1 and IL-6 can induce acute phase proteins and are generally considered to be pro-inflammatory
[251, 252]. IL-1 has been shown to be increased in inflammatory bowel disease during the active
phase [253]. Additionally, those values are expected to be high shortly after colonic injury and dur-
ing tissue repair [254]. The higher IL-1β levels therefore indicate that the BMDMs from Nlrc3-/-
mice are more effected by the LPS stimulation, indicating a protective effect of Nlrc3 in murine
BMDMs. The finding for IL-6 agrees with published findings in THP-1 cells [51] and indicates
a negatively regulatory role of Nlrc3 in signaling. Preventing a high pro-inflammatory IL-6 level
is furthermore in concordance with the hypothesis of a protective Nlrc3 behavior. Plasma level of
IL-1β and IL-6 have been studied in connection with IBD [255]. IL-1 levels were elevated during
flares of acute disease, fitting well to the higher values in Nlrc3-/- BMDMs. Hiscott et al. pub-
lished that NFκB is a potent inducer of IL-1 [256] giving a further potential connection to Nlrc3.
The CXCL-1 level dramatically increased after 2 hours and remained elevated throughout the next
six hours, a behavior which is in concordance with earlier findings [168]. The higher chemokine
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level in Nlrc3-/- is indicating an increased macrophage recruitment, which could lead to a stronger
immune response. IL-12 was induced by LPS administration, but shows no significant pattern or
distinction between Nlrc3-/- and Nlrc3+/+. Schneider et al. confirmed that the expression of pro-
inflammatory cytokines is increased in LPS-treated Nlrc3-/- macrophages [51].
5.4.2 Anti-inflammatory cytokine IL-10 is upregulated in Nlrc3-/- BMDMs
Since NLRC3 has been described as negative regulator for T cell function [50] it was tempting
to speculate on the effect on IL-10 as both seemed to signal along the same direction. The results
show that IL-10 is upregulated in LPS stimulated BMDMs of NLRC3-/- mice after two hours.
Compared to IL-6 the effect is weaker and shorter (Fig. 4.21). It is therefore hypothesized that
IL-10 acts as a mediator, modulating the cytokine induced response, but that cellular capacity was
out-ruled after 2 hours of LPS administration. Even though the delineation between acute and
late phase interleukin are not fully defined, theses results suggest, that Nlrc3 is involved in the
mediation of the acute phase interleukins.
IL-10 is mainly produced by macrophages, T cells, and B cells [257], and acts as a potent sup-
pressor of macrophage and T cell function. IL-10 inhibits the production of cytokines such as
IL-1, IL-6, and TNFα after LPS stimulation [258]. IL-10 deficiency in mice resulted in a lack
of regulatory T cells responsible for controlling the inflammatory response in the intestine [259].
The use of IL-10, or IL-10 producing bacteria as treatment for IBD patients is controversially dis-
cussed [260, 261, 262, 263]. Goblet cells and mucus do not seem to differ between IL-10 WT and
KO mice, but IL10 deficient mice produce a mucus penetrable for bacteria sized beads [7]. IL-
10-null mice develop a severe colitis driven by the microbiota [159]. Having determined a higher
IL-10 level in Nlrc3-/--BMDMs after LPS stimulation we expected to see an increased effect in a
DSS-induced colitis.
5.4.3 Translation of murine results to human systems
A high susceptibility of BMDMs for LPS stimulation and a strong reaction with respect to IL-6
and IL-12 were observed (Fig. 4.21, 4.22).
Wang et al. published recently a comparison of different macrophages with respect to their cy-
tokine expression, capacity for proliferation, and phagocytosis [250]. Their data showed, that bone
marrow derived macrophages possess a high basal IL-10 expression, which decreased after LPS
stimulation and a vice versa IL-6 and IL-12 expression. Although their results were gained in
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BALB/c mice they are supporting the data evaluated for this thesis. Schneider et al. used peri-
toneal macrophages of Nlrc3-/- to analyze the cytokine response to a LPS stimulus. These data
confirm the strong increase in IL-6 and IL-12 level. This includes the tendency of Nlrc3-/- to ex-
press higher levels than the WT in early stages of the experiment and an approximation in later
stages [51]. The work of Wang et al. and of Schneider et al. differ with respect to the IL-10 ex-
pression. The BALB/c mice of Wang et al. behaved opposite to the findings presented here, while
IL-10 expression was not tested by Schneider et al. [51, 250].
It might be questioned in how far the results gained in a mouse model are representative for human
applications. Arrifin et al. reviewed this question with regard to NLRs and pointed out, that genetic
divergence is relatively low in NLRs. Although the amount of presently known receptors differs
between the species, the biological outcome initiated by DAMPs is highly conserved [264].
5.5 Splenocytes exhibit surprising behavior upon stimulation
Splenocytes do require a 24 h pre-stimulation with P/I to respond to further stimuli. The com-
position of the splenocytes has been assessed via FACS analysis. Nlrc3-/- splenocytes showed a
significant elevated B cell level, while CD4+ were depleted. In general T helper cells (CD4+), cy-
totoxic T cells (CD8+), Memory cells (CD4- or CD8+) or Tregs (mostly (CD4+)) were expected.
Additionally, Nlrc3-/- splenocytes seemed to cope better with pro-inflammatory stimuli (Fig. 4.23),
resulting in a better survival. This is a still puzzling result, compared to the vast amount of data
suggesting a cytoprotective feature of Nlrc3.
5.6 DSS colitis
A DSS-induced colitis in mice is a suitable model for severe intestinal inflammation. Although
NLRC3 was not highly expressed in the intestinal tract during normal conditions, the proposed
immune receptor activity might be elucidated during severe inflammation.
5.6.1 Nlrc3-/- mice display a stronger onset of disease
The current experiment facilitated three groups of animals, an untreated control group, Nlrc3+/+,
and Nlrc3-/- mice, which received 4 % DSS solved in the drinking water. All animals were male as
they were described to be slightly more susceptible for DSS colitis [167]. The severity of the DSS-
induced etiopathology was measured as the disease activity index. The DAI can value between
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0 and 15 points, increasing with disease progression. As shown in Fig. 4.28 A both, WT and
KO, displayed an increasing DAI. A significant difference was detectable on day six, showing a
peak for the KO animals. The difference disappeared in the following two days. The weight loss
and obviously the whole disease progression continued after the DSS containing drinking water
was replaced by pure autoclaved tap water. This seems to be an intrinsic feature of the C57BL/6
background [265].
The Nlrc3-/- mice displayed a stronger onset of disease, marked by an earlier body weight loss (Fig.
4.28 C). Day five has been the critical turning point in disease progression. Both genotypes were
heavily affected by DSS treatment (Fig. 4.28 A-C). The MEICS score is based on observations
exemplary depicted in Fig. 4.26. The marks seen in both genotypes resemble the expected signs
as published by Becker et al. [187].
The colon length has been normalized to the body weight. A general shortening of the colon was
observed when compared to the untreated controls, but the genotypes showed the same trend (Fig.
4.27) This is supported by earlier findings [160]. The spleen weight, which would be expected to
be increased in heavily inflamed state showed no significant difference even when compared to
the control. The same observation holds true for the spleen length. These findings are supported
by recently published data, stating that the spleen size could not be expected to be increased prior
day 12 [265]. This proxy would accordingly be interesting for longer or chronic DSS experiments.
The histological staining were checked for signs of neoplasia, but the indication was negative. The
tissue samples of DSS treated mice displayed a severe alteration in tissue structure and organiza-
tion. The mucus layer seems to be eradicated, crypts lost, and the general tissue structure wreaked.
Additionally, the HE-score was assessed, giving an indicator for the severity of colonic tissue
damage [205]. As seen in Fig. 4.29 both genotypes are heavily affected, displaying heavy tissue
integrity loss, restructuring, and immune cell invasion. The Nlrc3-/- mice were affected most (Fig.
4.29 D). The HE score was evaluated in a blinded setup and revealed a significant higher value
for the Nlrc3-/- samples. Additionally, a yet not described change in the colonic structure of Nlrc3
WT and KO mice was observed. The DSS treated animals displayed crypt abscesses in the villi.
Comparing representative count of those structures, revealed a significantly increased amount in
the Nlrc3-/- animals (Fig. 4.30). Summarizing the basal disease values it has to be stated that Nlrc3
seems to have a cytoprotective effect.
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5.6.2 NFκB increased in DSS treated mice
Following the earlier findings of NLRC3 being involved in NFκB signaling, colon tissue was pre-
pared and stained with an α-NFκB specific staining (Fig. 4.33). The NFκB level were increased in
all DSS treated samples, showing a clear response to the administration of strong pro-inflammatory
drugs. This finding is in concordance with NFκB activation in human IBD [266]. In comprehen-
sion with the comparable disease progression in both genotypes, the NFκB level seem to be equal.
A deletion or decrease of NFκB could lead to apoptosis of colonic epithelial cells, impaired ex-
pression of antimicrobial peptides and translocation of bacteria into the mucosa [267].
5.6.3 Interleukin levels are altered in DSS treated Nlrc3-/- mice
As shown in the interleukin screening of LPS stimulated BMDMs IL-10 seems to be elevated in
Nlrc3-/- mice (Fig. 4.21). Kühn et al. suggested, that the absence of IL-10 is associated with gut
inflammation [159]. Several of the above mentioned experimental results indicated a protective
role of NLRC3. To solve this contradicting data the interleukin level were assessed on transcript
and expressed cytokine level. The transcript level of IL-6 and IL-10 were determined in colon,
spleen, and mesenchymal lymph node cDNA (Fig. 4.32), while the cytokine concentration of
IL-6, CXCL1, and IL-10 was measured in serum (Fig. 4.31). It is interesting to mention that IL-
10 interferes with the NFκB pathway, by inhibiting it [268, 269], therefore signaling along with
NLRC3.
The transcript level showed no significant difference between WT and KO, but were generally
elevated compared to the control. The highest increase compared to the control was measured in
the colon, which is the organ most affected by DSS colitis. The trend which has been visible in
the LPS stimulated BMDMs was affirmed here. A study in colonic tissue homogenates by Melgar
et al. showed, that the cytokine level of IL-1, IL-6, and IL-18 rapidly increased within their first
days of DSS colitis compared to healthy mice. The IL-6 values showed a 513 fold difference
after 5 days [265], which is confirmed by the findings shown in Fig. 4.32. The Nlrc3-/- mice
seem to have slightly elevated IL-6 and IL-10 values compared to the wildtype, but drastically
increased values compared to the untreated controls. The expression pattern of cytokines over
time might interfere with these results, as it has been shown, that e.g. IL-10 expression alters
greatly after the critical point in disease progression [270]. The upregulation of IL-6 is consistent
with findings in IBD [271]. This implicates, that Nlrc3 mediates or downregulates the production
of interleukins as an indirect response to several inflammatory stimuli, such as LPS and DSS. It
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has been recently published, that IL-10 seems to have an inhibiting effect in colitis [272]. The
IL-10 transcript level in all three tested tissues was increased in DSS treated animals, but no such
effect was measured in serum samples. A positive effect of the anti-inflammatory cytokine IL-10
is therefore plausible, but could not be affirmed by the current experiments. The serum level of
IL-6 and IL-10 revealed a statistic significant difference in CXCL-1. The CXCL-1 trend is partly
in concordance with the findings in LPS stimulated BMDMs. The CXCL-1 levels boosted after
two hours not discriminating between the genotypes. Nevertheless the levels tended to remain
higher in KO animals. It has to be highlighted that both experiments facilitated different cell types
and that the DSS samples were taken at an uncertain point in time after the primary stimulus
(bacterial contact to exposed lamina propria). The experiment showed clearly, that a disruption
of the colonic mucus as a result of DSS administration contributes to a severe inflammation. The
exact moment of the first contact and therefore the possible peak of CXCL1 release in vivo could
technically not be monitored. CXCL-1 has been described as a neutrophil chemoattractant KC.
CXCL1 deficient mice exhibit increased susceptibility to DSS-induced colitis [168].
5.6.4 Nlrc3 influences mtUPR marker
The transcript level of pkr, cpn60, and grp78 were monitored as hallmarks for mtUPR (Fig. 4.34).
The mitochondrial cpn60 is responsible for the refolding of proteins after mitochondrial stress
events [273]. A SYBR Green assay in ileum samples of DSS treated mice, showed a slight decrease
of cpn60 and grp78 level, compared to the untreated control. A significant and overall alteration
of mtUPR marker was not detectable in this study design, recommending a screen in more tissues
and after longer exposure to DSS.
Rath et al. published a potential link between mtUPR and inflammatory bowel diseases as cpn60
and pkr were induced in intestinal epithelia cells of murine colitis models and in human inflamed
IBD samples [206]. The data were gained in mice on a 129SvEv background, in two consecutive
7 day 1 % DSS cycles. Especially the double-strand RNA activated protein kinase PKR seems to
be a central link between sensing and inflammatory response [274]. They stated further, that pkr-/-
mice failed to induce cpn60 under a short-term DSS feeding protocol [206]. As the pkr values
do not significantly alter in the DSS experiment presented here, a cpn60 alteration seems to be
unlikely, resulting in no accelerated disease progression due to pkr induced cpn60.
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5.6.5 Final conclusions on DSS experiment
Concluding the results gained from the 4 % acute DSS colitis it has to be stated, that the Nlrc3-/-
mice were doing worse than the wildtypes. This is demonstrated by a higher DAI, HE score,
altered CXCL1 serum level, and a significant increase in tissue damage/crypt abscesses. The DSS
colitis experiment therefore supports the hypothesis of a protective Nlrc3 function. Some proxies
assessed, such as the spleen size, might be different or more distinct after a longer exposition
of the mice to DSS. It might therefore be useful to establish a chronic colitis experiment with
a lower DSS-dose. Additionally, some values indicate strong tendencies, without being statistical
significant. This might be overcome by an experimental setup utilizing a higher number of animals.
For future experiments variations between DSS lots have to be mentioned. It has been published,
that the ability to induce colitis varies between lots, requiring an experimental approach for the
best concentration [168]. The chosen 4 % DSS in this thesis induced a severe colitis resulting in
two spontaneously fatal outcomes prior to the termination of the experiment. A dose of 2.5 % DSS
might be more suitable and reveal a more distinct difference between WT and KO.
It has been shown, that immunodeficient mice are able to develop DSS colitis, indicating that
the pathology is independent of B and T cells and therefore mostly driven by the innate immune
system [164]. Mice therefore provide a stable and convenient model for IBD and general inflam-
matory processes. Nevertheless, it has to be considered that different strains might impact the
experiments. The mice for this thesis were back crossed to a C57BL/6 background. A back cross-
ing to the also very common BALB/c background may have resulted in slightly variable results,
with respect to interleukine levels or T cell composition [167, 275, 276, 277]. A comprehensive
work comparing the results of DSS administration to C57BL/6 and BALB/c mice has been given
by Melgar et al.. It was shown that both strains developed the clinical symptoms of colitis, but that
the outcome and molecular response e.g. the cytokine production somehow differs. Additionally,
it was shown that a single 5-day DSS administration was capable to induce a chronic colitis in
C57BL/6 mice, while BLAB mice recovered [265].
5.7 Relevance of NLRC3 in several diseases
The results shown in this thesis demonstrate a participation of NLRC3 in inflammatory processes.
Thus far, no disease has been directly linked to a mutation or lack of NLRC3. The Nlrc3 knockout
mouse model employed in this thesis showed no visible alterations or basal changes in histology
(Fig. 4.16, 4.17) and is shown to be non-lethal. However ongoing research on several diseases
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found altered transcript levels of NLRC3.
5.7.1 NLRC3 is downregulated in Wegener’s granulomatosis patients
We were able to show that NLRC3 is downregulated on protein level in Wegener’s granulomatosis
patients Fig. 4.24. The same holds true for the transcript level where NLRC3 is downregulated
two-fold compared to normal controls. The altered expression of NLRC3 in WG samples indicates
a possible protective role in the context of inflamed respiratory mucosa. As tissue defects or an
increased infiltration of immune cells were not detectable [203], it might be concluded, that the
protective effect is independent of mucosal integrity. The gene regulation seems to be due to a yet
unknown mechanism.
5.7.2 Phase II dasatinib study: NLRC3 is downregulated, while NFκB2 is increased
A previous study by Amrein et al. showed that patients in a phase II study of the drug
dasatinib (N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-
pyrimidinyl]amino]-5-thiazole carboxamide monohydrate) in response to relapsed or refractory
chronic lymphocytic leukemia developed signs of brisk apoptosis. Enriched peripheral blood
lymphocytes consisting of B cells mostly were sampled and RNA extracted. A microarray gene
expression profiling 6 hours prior and after dasatinib application showed a significant downreg-
ulation of NLRC3, while NFκB2 was significantly up regulated [278]. The NFκB2 upregulation
might be useful to evade apoptosis [278, 279]. Due to a parallel downregulation of NLRC3 it is
tempting to speculate on a pro-apoptotic feature of NLRC3. It has to be questioned whether this
represents a protective effect in the complex interplay controlling apoptosis and a possible involve-
ment of mitochondrial processes. Although the statistical power in the latter study is relative low
and enriched peripheral blood lymphocytes were not used in the work presented here, the findings
provide another suggestion of the involvement of NLRC3 in NFκB signaling. In 2005 Conti et
al. proposed [50], and was later supported [51], that NLRC3 is indeed involved in T cell receptor
mediated signaling to NFκB.
5.7.3 NLRC3 is downregulated during aging
Additionally, it was shown that NLRC3 is downregulated during aging processes in peripheral
and intestinal leukocytes [280]. Rosenstiel et al. assumed that a downregulation of effectors of
the innate immune system diminishes the capabilities of the immune system with age, resulting
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in lower pathogen recognition and aberrant immune response which ultimately leads to morbidity
and mortality. A protective role of NLRC3 could be inferred, although the direct mechanisms still
remain unknown.
5.8 Summary
NLRC3 is a cytosolic protein with direct connections to signaling events of the innate immune sys-
tem. The main interactors of NLRC3 remain unidentified, but a mere TNFα stimulation decreases
NLRC3 in HEK-293 cells on protein level. LPS stimulation of WT and KO BMDMs resulted in a
distinct cytokine profile.
Cell fractionation and microscopic imaging indicated a close interaction of NLRC3 with mito-
chondria. Mitochondria are a central hub for immune regulation and cellular response, which
would further strengthen the impact of NLRC3 on immunmodulatory effects, without the necessity
of a single inducing PAMP. A theoretical model might follow the example of NLRX1 interacting
with mitochondria [19, 281, 282]. Initial work has been done in the field of mtUPR in connection
with NLRC3.
Whether the detection of PAMPs via NLRC3 is a direct ligand-receptor interaction or whether
complexes or cofactors are required is still elusive. NLRC3 has previously been shown to interact
with the E3 ligase TRAF6, modulating a NFκB response. Current results of a dual luciferase assay
are questioning the direction of regulation induced by TRAF6, but were able to show a significant
impact of NLRC3 on NFκB signaling. A cooperation between TLRs and NLRs might distinguish
between pathogen and commensal bacteria or modulate an immune response. Analysis of local-
ization, expression level, modulator capacity of the NFκB pathway and interleukin expression
profiling was ultimately followed by an acute DSS-induced colitis model. It could be shown that
the Nlrc-/- mice fared worse than the WT with respect to survival, tissue damage, and previously
undescribed crypt abscesses. NLRC3 has been described to be regulated in a variety of diseases, a
connection to WG could be shown in the cause of this thesis.
Reviewing all data gained, it has to be stated, that NLRC3 exerts a cytoprotective effect by modu-
lating immune response. NLRC3 is closely connected to mitochondria, especially the inner mito-
chondrial membrane protein IMMT and members of the mitochondrial unfolded protein response.
This thesis is one of the first systematic works on NLRC3, revealing new data and prospective




This thesis aimed to characterize the yet underrepresented NLRC3 protein. As neither its biolog-
ical function, nor its molecular signaling has been fully described previously, a broad spectrum
of analysis were conducted to assess these open questions. In the course of analysis several new
questions and possible connections arose, which could not all be followed up during this thesis.
Therefore the most striking of these questions a presented here, which might be interesting hints
for further research.
Mitochondrial UPR has been shown to interact directly with erUPR via common signaling
molecules, such as eIF2α and cJun [206]. Taking the current findings of ERSE activation and col-
itis linked mitochondrial stress into account, this might proof an interesting read out for acute and
chronic DSS experiments. Another potent inducer of mitochondrial stress are thapsigarin-induced
sepsis models [283]. The breeding of a Nlrc3-/- x Pkr-/- double knockout mice could be taken into
consideration. Beside the alternative induction of mitochondrial stress it would be useful to further
monitor cellular responses, such as ATP level and mitochondrial membrane potential. Latter has
been shown to be decreased by cytokine-induced ROS generation [284]. The ERSE experiments
showed, that an impact of nuclear signaling could not be ruled out, and mtUPR pathways are
known to facilitate mitochondria to nucleus signaling [71]. Finally, estrogen has been shown to
be an inducer of nlrc3 in the bony fish gilthead seabream [285]. It has been shown that estrogen
receptor mediates UPR resulting in an upregulation of proteasomal degradation and activation of a
cytoprotective response [286, 287]. These findings might further proof the hypothesis of protective
features of NLRC3.
Acid alpha-glucosidase, which is responsible for the lysosomal degradation of glycogen to glucose
has been found as a potential interaction partner of NLRC3 in a Y2H screen [data not shown].
Stimulation of dendritic cells with TLR agonists resulted in a switch to glycolytic ATP metabolism,
indicated by higher expression of glucose transporter while simultaneously decreasing the oxygen
consumption [288]. With regard to the close connection between NLR and TLR pathway this
might be interesting as a first indication has been given that glycolysis might act as a protective
mechanism in inflammation [289, 290].
Additionally, it would be interesting to investigate the time laps of disease progression of Nlrc3-/-
mice in a more detailed way. The present experiments showed, that day five marks the critical
turning point in disease progression. The necessarily preceding depletion of mucin, mucin wash
out due to diarrhea [291] finally resulting in an exposed lamina propria could not be monitored in
92
DISCUSSION
Nlrc3-/- mice yet. Experiments should additionally include an analysis of the impact of different
DSS (molecular weight and lot), the mucin, the colonic wet weight to determine collagen increase,
and the cytokine production including the pro-inflammatory TNFα [265, 270, 292, 293, 294]. Al-
though the visual inspection of the caecum [data not shown] did not show any obvious signs of
inflammation it might be worthy to include them into analysis [167, 295]. Following the results of
Baer et al. it might be interesting to assess the mucosal ATP level [296]. Together with the finding
that NFκB up regulates mitochondrial respiration, this might be a fruitful way to further connect
Nlrc3 with mitochondrial processes and inflammation if applicable [297]. Taking into consider-
ation, that NLR deficient mice host a different microbiota than the respective WT [14] it seems
to be urgent to test this hypothesis on NLRC3 animals to evaluate a possible cytokine profile al-
teration due to immunmodulatory activities of the gut bacteria [298]. An assay of transepithelial
electric resistance might reveal, whether Nlrc3-/- animals provide an increased intestinal perme-
ability [299, 300], which might correlate with one of the main effects of DSS [161]. Crossing
Nlrc3-/- mice with TRAF6-/- mice, could further clarify the interactions of TLR and NLR pathway.
Stimulation of TLRs may further lead to an interaction between p62 and TRAF6, resulting in
TRAF6 autoubiquitination, NFκB activation, and finally inducing pro-inflammatory cytokines
[301]. It has been stated that p62 accumulates upon selective disruption of the proteasomal degra-
dation pathway, resulting in altered cellular distribution patterns [302]. Early experiments with
NLRC3 indicated a proteasomal degradation of NLRC3 (Fig. 4.13), but initial experiments with
proteasom inhibitors failed to show a direct connection [data not shown]. The interactions between
TRAF6, NFκB, and p62 can be linked to protein kinases c, which itself is involved in the same
signaling pathways [303]. It has been proposed that the PKCι in the intestinal epithelium protects
against DSS-induced colitis [304]. Although the connection between NLRC3 and p62/pkc is yet





6.1 Isoforms of NLRC3
Several isoforms of NLRC3 have been published and deposited in public databases. The proposed
isoforms are partly lacking experimental confirmation. A graphical overview is given in Fig. 6.1.
Fig. 6.1: Proposed isoforms of human NLRC3 and murine Nlrc3. A Human and B murine isoforms of NLRC3 are
shown. Squares symbolize exonic and lines intronic regions. deleted sequences are indicated by a broken line, additional
or altered sequences are marked in red. Isoform 1 has been chosen as canonical.
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6.2 Generation of mice
The cloning and generation of mice was performed by genOway in close agreement with Prof. Dr.
Rosenstiel.
As depicted in Fig. 6.2 the homologous sequences were cloned as three independent fragments
obtained by PCR through the use of genomic 129Sv ES cell DNA. The oligomers are given in
Tab. 6.1.
Fig. 6.2: Murine Nlrc3 gene cloning. Diagram is not depicted to scale. Boxes represent exons, solid lines intronic
sequences. The approximate locations of oligonucleotides hybridization sites that were used for the amplification of the
homologue DNA fragments are indicted by arrows. The resulting fragments, their names and the respective expected
sizes are given.
Tab. 6.1: Oligomers for amplifying murine Nlrc3.
subclone oligo name sequence 5’-3’ fragment size [bp]
ROS1-LAdi ROS1-C1 ATCATGCACACATAGAACACTCACG 4499
ROS1-D1 CTGAGGGTCTTCATGTAACAAATGC
ROS1-LApr ROS1-A1 GTGACTGGTTTCTGCCTACGAGTCC 4040
ROS1-B1 CAGGTTCACTAGGGGCTGTGTTACC
ROS1-Samax ROS1-E2 GCTCTATTGTCAAAGCCTCAGGTGG 4090
ROS1-F2 GGAAGGGAGAAAAAGGAGAGAGTGC
The resulting product was cloned into pCR4-TOPO vector (Stratagene) via TA cloning. Several
subclones of each fragment were sequenced. The sequences were aligned against the C57BL/6
based consensus sequence available in the public database to determine polymorphisms between
C57BL/6 and 129Sv. The polymorphism rate was found to be less than 0.02 %. Several subsequent
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cloning steps were utilized to correct single point mutations, inserting the loxP-sites, the FRT-Neo-
FRT-loxP cassette and finally the Diphteria Toxin A cassette (Fig. 6.2).
The resulting targeting vector named ROS1-HR was homogenic with the embryonic stem cell
line 129Sv and contained the exons 2 and 3 of the Nlrc3 gene and was validated by sequenc-
ing. The loxP-sites enable the deletion under the action of a Cre recombinase, Diphteria Toxin
A was chosen as negative selection marker. The targeting vector ROS1-HR was linearized by re-
striction digestion via PacI. The resulting 15.6 kb targeting fragment was purified, transfected by
electroporation in 129Sv ES and positively selected after 48 hours by the aminoglycoside G418.
The positive selected clones were validated by a PCR screen, additionally the recombination was
confirmed by Southern blot. Recipient blastocysts were isolated from pregnant C57BL/6 females
(SPF conditions). Based on the screening results positive ES cell clones were injected in C57BL/6
blastocysts. The blastocysts were reimplanted into OF1 pseudo-pregnant females (SOPF status).
The pups gained were screened for their chimerism.
6.3 MS/MS
A full list of the MS/MS hits is available on the compact disc attached to this thesis.
6.4 Abbreviations
Abbreviations used in this thesis are enlisted in the following tables:
Tab. 6.2: Abbreviations. SI units were not enlisted.
aa amino acid
AD Acidic transactivation domain
AIM Absent in melanoma
ALP Absent in melanoma-2-like receptors
AP-1 Activator protein 1
ATF6 Activating transcription factor 6
b bases
BIR Baculovirus inhibitor of apoptosis protein repeat
BMDM Bone marrow derived macrophages
bp base pair
BSA Bovine serum albumine
CIITA Class II transcription activator
CARD Caspase recruitment domain
CD Crohn’s disease




Tab. 6.3: Abbreviations - continued.
Cre Cre Recombinase
CRS chronic rhinosinusitis with nasal polyps
CTL C-type lectin
CXCL1 Chemokine (C-X-C motif) ligand 1
Da Dalton
DAB 3,3’-Diaminobenzidine
DAI Disease activity index




DLB Denaturating lysis buffer
DNA Deoxyribonucleic acid
DSS Dextran sodium sulfate
ECL Enhanced chemiluminescence
EDTA Ethylenediaminetetraacetic acid
ELISA Enzyme linked immunosorbent assay
(s/r)ER Endoplasmatic reticulum (smooth/rough)
ERSE ER stress-responsive cis-acting elements
ESCIT Evolutionary conserved signaling intermediate in Toll pathway
FELASA Federation of European laboratory animal science associations
FIIND Function to find
FCS Fetal calf serum
FLP RMCE Recombinase
FRT FLP recognition target
g g force
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
GFP Green fluorescent protein





IBD Inflammatory bowel disease





IMMT Inner mitochondrial membrane protein, Mitofilin










Tab. 6.4: Abbreviations - continued.
LRR Leucine rich repeats
m milli
MAVS Mitochondria associated viral sensor
M-CSF Macrophage colony-stimulating factor
MEICS Murine endoscopic index of colitis severity
min minutes
mln mesenchymal lymph node




NACHT domain present in NAIP, CIITA, HET-E and TP-1
NALP NACHT, LRR and PYD domains-containing protein
NBD Nucleotide-binding domain
NC normal controls
NCBI National Center for Biotechnology Information
NLR NOD-like receptors
NOD Nucleotide-binding, oligomerization domain and leucine-rich repeat
containing protein
NFκB nuclear factor kappa-light-chain-enhancer of activated B cells
NLRC3 human NOD-like receptor CARD domain containing 3
Nlrc3 murine NOD-like receptor CARD domain containing 3
Opa1 Optic atrophy 1
PAMP Pathogen associates molecular pattern
PBMC Peripheral blood mononuclear cell
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PHA Phytohaemagglutinin
P/I PMA/Ionomycine
pkr double strand RNA-dependent protein kinase
PMA Phorbol 12-myristate 13-acetate
poly(I:C) Polyinosinic:polycytidylic acid
PRR Pattern recognition receptor
PRR Pattern recognition receptor
PVDF Polyvinylidene fluoride
PYD Pyrin domain
qPCR quantitative real time polymerase chain reaction
rb rabbit
RIG Retinoic acid inducible gene
RLR Retinoic acid inducible gene like receptors
RLU Relative luciferase unit
RMCE Recombinase-mediated cassette exchange
RNA Ribonucleic acid
RNAi Ribonucleic acid interference
ROS Reactive oxygen species
R protein Resistance protein
RT Room temperature
siRNA Small interfering RNA
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Tab. 6.5: Abbreviations - continued.
SPF Specific pathogen free
STAND Signal transduction ATPases with numerous domains
Taq polymerase from the bacterium Thermus aquaticus
TaqMan probes for real-time PCR
TLR Toll-like receptor
TMB 3,3’,5,5’-tetramethylbenzidine
TNF Tumor necrosis factor
TNFR TNF receptor
TOM Translocase of the outer membrane
TRAF TNF receptor associated factor
TTBS Tris-Tween buffered saline
U Unit
UC Ulcerative colitis






w/v weight per volume
XBP1 X-box binding protein 1
Y2H Yeast two-hybrid system
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